Arachnoiditis: leveraging crowdsourcing and AI in a cross-sectional study of 1,105 cases to improve identification, understanding, and treatment

Lori Verton[1], Noga Minsky[2,3], Eran Dotan[2,4], Roni Sharon[2,5], Megan Black[1], Patricia Gomes[1], Deepmala Rana Bhat[1,6], Shristi Sharma[1,6], Ishna Singh[1] and Linda Bavisotto[1*]

[1] Arachnoiditis and Chronic Meningitis Collaborative Research Network (ACMCRN), London, Ontario, Canada

[2] Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel

[3] Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Ramat Gan, Israel

[4] StuffThatWorks Ltd, Tel Aviv, Israel

[5] Department of Neurology, Sheba Medical Center, Ramat Gan, Israel

[6] Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada

***Correspondence:**

Linda Bavisotto

bavisotto@acmcrn.org

Abstract

Background

Arachnoiditis, a painful and potentially disabling neurological condition, results from persistent inflammation of the spinal cord pia-arachnoid membranes following injury. While considered rare, the condition is underdiagnosed. Research on symptomatology, diagnosis, and treatments is scarce, hindering clinical management. Artificial intelligence (AI) offers promising opportunities for rare diseases, enabling large-scale pattern identification. This study used traditional research methods coupled with AI technology to characterize patient-reported clinical presentation, comorbidities, aggravating factors, and treatments for arachnoiditis.

Methods

This retrospective cross-sectional study utilized data from StuffThatWorks (STW), an online crowdsourcing platform for people with chronic diseases. Multiple choice and free text responses were assessed both quantitatively and qualitatively. Novel AI/machine learning algorithms were used to further analyze the data, including the STW cross-condition score (higher scores more indicative of arachnoiditis) and the STW treatment efficacy model generating effectiveness and detriment estimates, with binomial proportion 90% confidence intervals.

Results

Of 1250 international participants, 1105 reporting a physician-confirmed diagnosis were included. Participants were predominantly USA-based (71.4%), female (75.9%) and ≥46 years

old (73.1%). Of 712 symptoms grouped into eight categories, eighteen were more indicative of arachnoiditis (by cross-condition score). The most frequent symptoms were lower back pain (43.5%), leg pain (41.6%) and back pain (39.1%). Prolonged sitting (62.5%) and prolonged standing (58.3%) were the most common aggravating factors. Comorbidities were led by degenerative disc disease (32.3%), spinal stenosis (25.3%) and fibromyalgia (25.0%). The most frequently used treatments were gabapentin (37.9%), physiotherapy (30.1%) and pregabalin (26.5%). Treatments with the highest patient-rated effectiveness (by STW model, 90% CI) were low-dose naltrexone (28.1%, CI 20.0-37.0), ketamine infusion (24.8%, CI 16.9-33.4) and fentanyl (21.1%, CI 14.7-28.1). Epidural corticosteroid injections showed the highest detriment (38.5%, CI 28.0-45.9).

Conclusion

As the largest observational study of arachnoiditis to date, made possible with novel methodological approaches, this work offers new insights with potential to improve diagnosis and management.

Keywords

Arachnoiditis, Artificial intelligence, Chronic meningitis, Spinal diseases, Leptomeninges, Neuroinflammation, Chronic pain, Patient-reported outcomes, Radiculopathy, Rare diseases

Background

Arachnoiditis is a painful, potentially debilitating neurological condition resulting from persistent inflammation of the spinal cord pia-arachnoid membranes (leptomeninges) and the subarachnoid space between them [1–3]. A cascade of neuroinflammation in response to injury—a normally healthy mechanism, but persistent or excessive in arachnoiditis—results in early spinal nerve swelling and leads to thickening and clumping of spinal nerve roots [1,3,4]. The process can be focal or diffuse, and over time becomes compounded by the development of permanent scarring and adhesions, entrapping nerves and disrupting the normal flow of cerebrospinal fluid (CSF) in the subarachnoid space. Fibrosis and CSF flow disturbances can lead to spinal cord tethering, syrinx formation, myelomalacia, spinal cord atrophy, and myelopathic symptoms [1,2,5–9].

Arachnoiditis manifests with a wide spectrum of clinical presentations, and the course of the condition is highly variable [10]. Advanced stage adhesive arachnoiditis is commonly characterized by intractable neuropathic pain, significant mobility issues and myriad neurologic impairments [1,9,11]. Complications can extend to the genitourinary, gastrointestinal and autonomic nervous systems [12,13]. Together, these disease expressions can lead to significant morbidity, disability and shortened lifespan [3,13,14]. Considered a rare condition, but often misdiagnosed and overlooked, much remains unknown about the epidemiology and natural history of arachnoiditis, or the efficacy of interventions [1,15].

Clinical symptoms of arachnoiditis can appear acutely within hours or days of an inciting event, or develop gradually over months to years, or even decades, often leading to delayed diagnosis or misdiagnosis [1,9,11,16]. The condition may be triggered by a variety of

factors, primarily involving physical damage or chemical injury to the spinal cord, or by infection of the spinal meninges. Injury may occur because of trauma to the spinal cord, subarachnoid hemorrhage or other introduction of blood into the CSF, edema, or post-surgical or post-procedural inflammation [1,5,17,18]. Exposure of the meninges and CSF to a variety of chemicals has also been documented to cause arachnoiditis, with offending agents including intrathecal chemotherapy, corticosteroids, oil-based radiographic contrast agents, detergent solvents, contaminants, and preservatives such as polyethylene glycol, to name just a few [1,19]. Infectious meningitis can be caused by fungal, bacterial, viral, or parasitic pathogens [1,20]. Chronic meningitis, or aseptic arachnoiditis, are terms sometimes used to refer to inflammation without evidence for a causal infectious pathogen. The condition can also be triggered by autoimmunity, for example as an adverse immune event due to immune checkpoint inhibitor therapy of various malignancies [21]. In addition, idiopathic cases are not uncommon [1,22].

Whereas arachnoiditis arising as a late complication of meningeal infection may favor cervical and thoracic spine distribution [1], where the disease tends to be more progressive [2], the current predominance of lumbar arachnoiditis appears to be related to an increasing frequency of invasive lumbar spinal interventions, including various surgical techniques as well as epidural anesthesia and injections. Iodinated oil-based myelographic contrast imaging agents, such as iophendylate, administered via lumbar puncture into the subarachnoid space, have been associated with the development of numerous cases of iatrogenic arachnoiditis [1,4,14,19], and these agents were subsequently removed from the market. Fungal meningitis and arachnoiditis were documented in a number of clustered cases arising from contamination of methylprednisolone in epidural injections in 2012 [23–25] and of spinal

anesthesia in 2023 [26]. An updated American practice advisory was issued in 2017 on the prevention, diagnosis and management of infectious complications associated with neuraxial techniques [27].

It is important to emphasize that most individuals with the aforementioned exposures do not develop arachnoiditis. Some individuals may have underlying risk factors that predispose them. There appears to be an association with pre-existing anatomic spinal abnormalities as well as age-related degeneration, particularly in lumbar arachnoiditis [3,7,14,28,29]. These conditions in turn also lead to increased invasive spinal interventions, with multiple spinal interventions (of any kind) or traumatic procedures being more closely associated with the development of arachnoiditis [1,4,30]. There may be an increased risk in persons with auto-immune or systemic inflammatory conditions, such as autoimmune vasculitis, ankylosing spondylitis, mixed connective tissue disease or rheumatoid arthritis [1,31–33]. Additionally, a potential association with genetic connective tissue disorders, such as Ehlers-Danlos Syndrome (EDS), has been described in a limited number of studies [34,35]. Rare cases of familial arachnoiditis with syringomyelia have been documented [36], suggesting the possibility of an unidentified genetic susceptibility component in these individuals. A potential association between arachnoiditis and Tarlov (perineural) cysts has also been reported [34,37,38]. Various authors suggest that, in many cases, arachnoiditis is likely to result from a combination of risk factors or inciting events [4,14,34,39].

Diagnosis of arachnoiditis is based on individual history, clinical findings and MRI features. MRI is the preferred imaging modality, although CT myelography may be used when MRI is contraindicated [29]. Over the past 50 years, several staging classification systems for arachnoiditis have been proposed and modified based on symptoms, histopathology,

130 morphology and patterns of radiographic progression [14,40,41]. Expanding upon the
131 pathognomonic radiological patterns first established in the 1980s [40,42], recent diagnostic
132 studies of advanced stage adhesive arachnoiditis show that MRI findings may include
133 abnormal clumping and irregular distribution of spinal nerve roots, abnormal nerve root
134 contours, nerve root enhancement, synechia, loculated and typically dorsal arachnoid cysts,
135 as well as signs of CSF flow disturbance [10,28,29,43]. While radiological staging
136 classifications have focused primarily on lumbar arachnoiditis, disease occurring in other
137 spinal areas and the brain may be even more difficult to characterize on MRI [44–46].
138 Several limitations complicate the diagnosis of arachnoiditis in clinical practice.
139 Imaging findings are highly variable [29], and correlate poorly with symptom severity [43,47]. In
140 the cervicothoracic spine, neurosurgical observations show that MRI often incompletely
141 visualizes the extent of chronic arachnoiditis, especially focal arachnoiditis [44,45]. In the
142 lumbar spine, endoscopic surgery suggests that, in some cases, MRI may fail to identify the
143 condition at all [37,48,49], leading some authors to propose that mild arachnoiditis may be
144 overlooked in patients with unexplained lumbar radiculopathy symptoms but normal MRI
145 studies [50]. Adding to these diagnostic challenges, acute iatrogenic lumbar arachnoiditis may
146 initially present with minimal MRI findings – early imaging may show only nerve root
147 enhancement before other characteristic features develop, or may appear entirely normal [51–
148 55].
149 To address these limitations, several diagnostic methods have recently been described.
150 In the cervicothoracic spine, specialized MRI sequences and morphometric analyses for
151 improving visualization or inferring diagnosis have been employed [44,56–59]. In the lumbar
152 spine, proposed approaches include prone MRI to detect failure of the nerve roots to migrate

153 ventrally with gravity due to nerve root tethering [60], and morphometric analysis to assess for
154 mildly enlarged thecal sac dimensions [22,48,61,62]. MR neurography of the lumbosacral
155 plexus has also detected arachnoiditis not otherwise apparent on standard MRI [63]. In the
156 absence of a definitive diagnostic test and reflecting a lack of clear consensus in the field,
157 Epstein and Agulnick [47] have suggested that a characteristic constellation of symptoms
158 alone should suffice to make the clinical diagnosis of lumbar arachnoiditis, without the
159 requirement for radiographic confirmation.

160 Early and accurate diagnosis is important, as some therapeutic options for
161 arachnoiditis may be more effective when given in the initial stages of neuroinflammation.
162 When the diagnosis is not definitive, however, early intervention may be delayed to avoid
163 possible complications. In those with recent onset, early stage arachnoiditis, a variety of anti-
164 inflammatory, fibrinolytic, and immune-suppressive therapies have been empirically offered in
165 an attempt to arrest or slow the process of fibrosis and neuropathic progression
166 [1,12,53,64,65]. According to several recent reports, high-dose corticosteroids administered in
167 the earliest stages of acute arachnoiditis, often in iatrogenic cases, have led to recovery in the
168 short term [52,53,64,66,67]. However, the evidence is mixed, not all patients respond or
169 respond completely, and some patients recover spontaneously [1,52]. Most reports are
170 missing sufficient details. Further studies with standardized treatments and long-term
171 outcome assessments are needed as a critical research priority.

172 In patients experiencing progressive neurological deterioration, surgical intervention
173 such as detethering procedures, adhesiolysis, cyst fenestration, and decompression of
174 intradural arachnoid cyst or syrinx with or without shunting may be indicated
175 [1,2,5,44,62,68,69], however these procedures carry inherent risks of potential further

176 compromise in neurological function as well as development of post-operative inflammation
177 and scarring, which may lead to arachnoiditis recurrence. The primary surgical objectives are
178 to restore or improve CSF flow at sites of obstruction and to alleviate spinal cord compression.
179 The majority of contemporary literature on surgical management report on cases of
180 thoracic and cervical arachnoiditis, although some have included lumbosacral cases [5].
181 Favorable surgical outcomes have been reported, particularly early in disease prior to
182 significant spinal cord damage [2], although follow-up is often short and information
183 incomplete. There is relatively consistent evidence indicating that patients with focal spinal
184 involvement of arachnoiditis (limited to several vertebral segments) have better surgical and
185 neurologic outcomes post-operatively than those with extensive/diffuse spinal involvement
186 [2,44]. Minimally invasive neurosurgical approaches such as percutaneous intrathecal
187 endoscopy continue to evolve [37,48,49,62,70,71] and are sometimes combined with limited
188 laminectomy procedures [2,69] to allow direct visual assessment and safe removal of
189 adhesions in spinal segments adjacent to the laminectomy margins, extending the range of the
190 surgeon's reach beyond what would be possible with conventional laminectomy.
191 For patients who are not surgical candidates, management focuses on symptom-
192 directed supportive care and comprehensive chronic pain management [72,73]. Current
193 pharmacological and non-surgical interventions have variable results, typically providing
194 modest symptom relief at best, often with limited long-term benefit [1,3,11,12].
195 Substantial hurdles have impeded studies regarding the diagnosis, natural history and
196 treatments for arachnoiditis. One challenge is the lack of standardized terminology for
197 arachnoiditis across its varying degrees of severity, with Palackdharry et al. identifying up to 63
198 different terms used across specialties [1]. Determining clinically significant pathology also

199 remains unclear [74,75]. In addition, because arachnoiditis spans multiple specialties without
200 fitting neatly within one, research is fragmented [74]. Consequently, limited literature exists
201 regarding pathophysiology, symptomatology and accurate diagnosis, rendering correct
202 identification of the condition difficult. Inaccurate diagnosis may be common, as reflected by
203 poor inter-rater reliability (kappa score 0.05) in a 2021 study where five specialized radiologists
204 reviewed MRI images from 96 patients with hallmark criteria of the disease [28]. The
205 inconsistent lag times between insult and clinical presentation may further contribute to
206 delayed and missed diagnosis [10,61]. Chronicity of symptoms and the presence of
207 comorbidities may also complicate the clinical picture.

208 In recent years, the advancement of bio-registries, online patient advocacy groups,
209 digital health platforms, and disease registries, along with big data analytics, have begun to
210 overcome financial and logistical hurdles to understanding and treating rare diseases. In
211 addition, there has been increasing interest in arachnoiditis, with the number of publications
212 growing [1,76]. Following a collaborative research network model in which patient-led
213 initiatives have successfully accelerated research into rare diseases [77-78], the Arachnoiditis
214 and Chronic Meningitis Collaborative Research Network (ACMCRN) [79] advocated for the
215 establishment of an arachnoiditis research community on the digital health platform
216 StuffThatWorks (STW) [80]. The platform is structured to enable community-driven research
217 and insights. This study represents a retrospective analysis of the data accumulated through
218 this initiative in order to help advance understanding of the condition. It characterizes the
219 symptoms, aggravating factors, comorbidities and treatments among a large cohort of
220 individuals living with arachnoiditis. This work serves as a prelude to the creation of an

221 international arachnoiditis patient registry and the development of further studies.

222

223 Methods

224 Study design and data collection

225 This study is a retrospective cross-sectional analysis of observational patient-reported
226 data collected by STW [80]. STW is a free commercial crowdsourcing digital health platform
227 with approximately 2.9 million members across 1,261 medical conditions at the time of this
228 writing. It provides an online venue for people living with specific medical conditions to
229 voluntarily share structured information about their symptoms, treatments and outcomes
230 within condition-specific groups, termed "communities". This information is de-identified and
231 aggregated into community insights that form an accessible organized knowledge database,
232 enabling community members to self-educate. Natural language processing and machine
233 learning algorithms aggregate and analyze entries to generate insights about age of onset,
234 symptoms, aggravating factors and treatments. After several hundred responses are collected,
235 the algorithm ranks treatments according to effectiveness; with larger numbers of responses,
236 the model estimates the probability of treatment effectiveness based on user assessments.
237 Participation in the STW online survey platform is entirely voluntary, confidential and
238 anonymous, and participants retain the right to opt out of the platform and data sharing at any
239 time. Each of the STW chronic disease communities utilizes a common English-language,
240 structured medical questionnaire. This includes demographic items as well as aspects of
241 medical history, such as symptoms, diagnosis, treatments, aggravating factors, clinical
242 indicators, and comorbidities, along with assessments of quality of life and daily functioning.

With the exception of several mandatory questions, including current age and sex at birth, participants are free to disclose only information they want to share.

For the purposes of the current retrospective study, survey data were accessed in January 2023 and provided to the authors in aggregate format, with age categories, rather than precise age. Compiled data comprised participant responses to a questionnaire, including current age, sex at birth, age at symptom onset, symptoms, aggravating factors, comorbid conditions, and all previously attempted arachnoiditis treatments (including medicines, supplements, procedures, protocols, dietary changes, alternative or complementary therapies, classes). Supplementary Material 1 lists the specific STW survey questions used in the data analysis for this study. Many survey questions used open-text fields so as not to limit responses to a predetermined list. This exploratory approach necessitated that compiled results include both qualitative and quantitative data.

Participants

Participants were users of the STW platform who voluntarily joined the condition-specific arachnoiditis community through multiple pathways, including organic discovery as well as promotion by ACMCRN [79]. ACMCRN, a patient advocacy and research organization, raised awareness of the arachnoiditis research community on the STW platform by drawing on its existing networks through social media and word-of-mouth. ACMCRN had no financial arrangement with STW and offered no incentives to participate on the STW platform. To be included in the study analysis, participants had to indicate that their arachnoiditis was diagnosed by a physician.

Data analysis

Responses to open-ended questions were coded into structured entities using STW's proprietary "normalization tool" as a component of natural language processing. For example, for a question regarding main symptoms, the answer "leg weakness and tingling" would be normalized into two different "symptom" entities: "leg weakness" and "leg tingling". Numbers for each response were given out of the total number of valid responses (n), after exclusion of patients who did not answer the question and responses that were not normalized successfully by the normalization tool.

Quantitative data are reported as frequencies and percentages. Quantitative results also include values derived from an innovative algorithm unique to STW, the proprietary "STW cross-condition score". This score uses AI-based models to measure how specific an entity or response is to one disease community when compared to all other chronic disease communities on the platform. The scale ranges from 1-10, with a score of 10 for an entity (such as a symptom, aggravating factor or comorbidity) which is very commonly reported in one community (e.g., arachnoiditis) but is rarely reported in others. Thus, higher scores indicate higher specificity for the condition of interest. A cross-condition score ≥ 6 is highly indicative of a given condition; a score between 3-5 is moderately indicative for the condition; and a score < 3 is a weak indicator for the condition. Novel research approaches are increasingly recognized as important for advancing understanding of rare diseases [81]. Given that results from other STW analytical models have demonstrated consistency with traditional research findings [82-

286 83], the authors included the cross-condition score data in addition to standard research
287 results.

288 To evaluate treatment effectiveness, alongside the primary data, a proprietary STW
289 treatment efficacy model was used [82-84]. Treatment effectiveness was expressed as an
290 estimated ratio of how many respondents rated a treatment as effective, out of the total
291 number of reports of this treatment (i.e. number of effective reports/numbers of tried reports),
292 while accounting for the level of certainty in the estimate based on the overall number of
293 reports for each treatment. A hierarchical Bayesian calculation generates a binomial
294 proportion confidence interval around the estimated proportion. To prevent overestimation of
295 the effectiveness of rarely used treatments, the model accounts for the number of reports on
296 each treatment, such that treatments with many reports are given greater weighting than those
297 with few reports. The model does not distinguish between treatments which were taken for
298 specific symptoms but rather assumes that all treatments are targeting the condition as a
299 whole. The output is expressed as a percentage together with a 90% confidence interval.

300 Where a large volume of findings was captured from open-ended questions, results are
301 presented according to a combination of both quantitative and qualitative methods.
302 Qualitative analysis utilized content analysis methodology and categorization [85] of like
303 responses for symptoms and aggravating factors, where ≥ 1% of the total study population
304 entered the same response. This analysis enabled a detailed exploration of the full breadth of
305 responses. In the absence of substantial prior research, qualitative methods are critical for
306 generating insight, and, in the context of rare diseases, mixed method approaches are valued
307 for incorporating lived experiences as meaningful input [86-87]. Although three authors (MB,

LB, IS) did the content analysis and categorization, all authors agreed upon the final categorization of qualitative data.

The STW proprietary tools used in this study were applied within the platform environment. Subsequent to the data extraction performed by STW, the aggregated outputs generated by these models were shared with the authors, who have further analyzed and interpreted them in this report. No modifications to the underlying algorithms were made for the purposes of this study.

At the conclusion of the project, ACMCRN offered a summary of aggregate study findings and insights to the arachnoiditis online support groups community in a series of publicized online webinars. The sharing back of results to the participant community reflects recognized ethical principles of reciprocity and respect for participants' contribution to the research.

Ethics and data protection

Participation in the STW platform is voluntary, and the platform is designed to be transparent to its users, including in its use of artificial intelligence. Individuals join to share experiences related to specific health conditions and benefit from access to insights generated from their aggregated community data. At registration, before sharing any data, users agree to the platform's terms of use and privacy policy, which inform participants that user-contributed information is handled in de-identified form and may be used for research purposes, including secondary analysis by external researchers. The policies specify that any data shared externally will be provided in aggregated form only. Participants may withdraw

330 from the platform and discontinue data sharing at any time, retaining ongoing control over their
331 contributed data. For any participants under the age of 16 years, a parent or guardian was
332 required to register and complete the questionnaire on their behalf.

333 STW obtained ethics approval from the Helsinki/IRB Committee of Sheba Medical
334 Center (Ramat Gan, Israel; protocol #7356-20-SMC) for the collection and analysis of de-
335 identified data for medical research across its chronic disease communities. This study
336 analyzed de-identified, routinely collected data from the STW digital health platform,
337 presented to the authors in aggregate form. Given that each participant had previously
338 consented at registration to the use of their de-identified data for research purposes, including
339 by external researchers, and that secondary analysis of existing data posed minimal risk of re-
340 identification—a key ethical consideration in digital health platform use [88]—the Sheba
341 Medical Center Ethics Committee approved a waiver of requirement for additional consent for
342 use of the medical questionnaire for research purposes. The present study falls within the
343 scope of this approval.

344 Data collected by STW are stored in a de-identified manner, with each user assigned a
345 non-indicative number. For the present study, data extraction and aggregation were performed
346 within the STW platform by one author (ED) who was affiliated with STW at the time the data
347 were accessed. The dataset provided to the remaining members of the research team
348 contained only aggregated information summarizing symptoms, treatments, aggravating
349 factors, and comorbidities at the population level. No individual-level data capable
350 of identifying or re-identifying participants were shared with the authors. This study therefore
351 represents secondary analysis of de-identified, aggregated user data. It was conducted in

352 accordance with the principles of the Declaration of Helsinki and consistent with recognized
353 ethical guidance for conducting health research with online communities [89].

354 Results

355 Demographics

356 Between July 2020 and December 2022, 1250 individuals enrolled on the STW platform
357 as members of the arachnoiditis research community. Of these, 1105 (88.4%) affirmed that
358 their diagnosis of arachnoiditis had been confirmed by a doctor, and only their data were
359 included in the study cohort for the following analyses.
360 Study participants were international, with the majority (71.4%) from the United States,
361 and three quarters (75.9%) were female. White or European ethnicities were predominant
362 among survey participants, while black or African American, Asian, and Hispanic ethnicities
363 were relatively underrepresented. Specific demographic characteristics of the study
364 participants are summarized in Table 1.
365

366 **Table 1. Demographic characteristics of 1105 study participants**

Characteristic	n	%
Sex (at birth)		
Female	839	75.9
Male	266	24.1
Country		
United States	789	71.4
United Kingdom	77	7.0
Canada	50	4.5
Australia	31	2.8
Germany	12	1.1
South Africa	7	0.6
Others	139	12.6
Age at time of survey [a]		
0-18 years	3	0.3
19-30 years	43	3.9
31-45 years	252	22.8
46-65 years	615	55.7
66+ years	192	17.4
Age at time of symptom onset [b]		
0-18 years	26	2.5
19-30 years	133	13.0
31-45 years	389	38.1
46-65 years	408	39.9
66+ years	66	6.5
Ethnicity [c]		
White	943	89.0
European	207	19.5
American Indian or Alaska native	45	4.2
Hispanic or Latino	45	4.2
Asian	20	1.9
Black or African American	16	1.5
Arab or Middle East	9	0.8
Body Build [d]		
Significantly underweight	25	2.2
Moderately underweight	78	7.1
Average weight	441	39.9
Moderately overweight	452	40.9
Significantly overweight	109	9.9

367 *n*, number of participants in each category
368 [a] Percentages sum to 100.1% due to rounding
369 [b] Not all participants reported age at initial onset (n = 1022)
370 [c] Totals for ethnicity are greater than 1105, and percentages exceed 100%, as participants were able to select
371 multiple responses for ethnicity, as applicable
372 [d] Body build was self-reported by participants

373

374 Participant age at the time of taking the survey and at the appearance of initial
375 symptoms are presented in Fig. 1. The majority of respondents at the time of the survey

376 (73.1%) were ≥ 46 years old. At the time of initial symptom onset there is a proportional shift to

377 the younger ages, with more than half (53.6%) ≤ 45 years.

378



379

380 **Fig. 1 Comparison of age distribution at time of survey and at onset of symptoms among**
381 **1105 participants.** Not all participants reported age at symptom onset (n = 1022).

382

383

384 ## Assessment of symptoms

385 Participants were asked to list their symptoms in order of severity. Almost all

386 participants (99.6%, n = 1101) responded to this question, including 74 respondents who listed

387 no specific symptoms. A total of 712 specific symptoms were described. Fig. 2 displays the 20

388 most frequently reported symptoms and their percentages, with color coding to denote

389 symptoms with STW cross-condition scores ≥ 6 (most indicative for arachnoiditis).

390

391



Fig. 2 Most common symptoms among 1101 study participants reporting symptom data. STW (StuffThatWorks) cross-condition score (scale 1-10): A score ≥ 6 is highly indicative for arachnoiditis, a score between 3-5 has a medium degree of indication, and a score < 3 has a low indication (see Methods). Solid bars represent scores ≥ 6.

Given the large volume of symptoms described (n = 712), the 10% most frequently cited (n = 71) were categorized into groups of like symptoms using content analysis methodology. This produced 8 main symptom categories: pain; symptoms of motor nerve damage or irritation; altered sensation; symptoms experienced in the feet; bladder or bowel issues; head and neck symptoms; difficulty with daily activities; and “other” (autonomic, gastrointestinal, endocrine, autoimmune, heat or temperature sensation, and not otherwise categorized). Analysis of the additional 67 symptoms reported by ≥ 1% of the total study population (i.e. ≥ 11

405 people) did not yield any further distinct symptom categories beyond those previously
406 identified.
407 Table 2 presents the symptoms in each category and corresponding percentages. STW
408 cross-condition scores (also shown for each symptom), revealed a hierarchy of symptoms
409 highly indicative of arachnoiditis (scores ≥ 6), with decreasing significance as follows: lower
410 back pain, legs pain, formication (feeling of something crawling on you), electric shock feeling,
411 burning sensation in feet, weakness in legs, numbness in feet, bladder issues, numbness in
412 legs, burning sensation in legs, numbness, back pain, muscle spasms, foot pain, burning
413 sensation, buttocks pain, shooting leg pain, and tingling sensation. Supplementary Material 2
414 provides a complete list of all symptoms reported by participants, ordered by frequency (n, %,
415 STW cross-condition score).
416

Table 2: Main symptoms by category

Categories	Symptoms Percent of participants (n=1101); STW cross-condition score[a]					
		%	score		%	score
Pain						
Spinal pain	Lower back pain	43.5	**7.21**	Back pain	39.1	**6.86**
	Spine pain	3.3	5.04	Lumbar region pain	3.1	5.65
	Pain across sacrum	2.9	4.99			
Referred pain	Legs pain	41.6	**7.12**	Burning sensation in legs	10.8	**7.00**
	Hip pain	9.6	5.59	Buttocks pain	8.7	**6.24**
	Sciatica	5.9	5.44	Shooting leg pain / radiating pain down leg	4.6	**6.17**
	Nerve pain in legs	4.5	5.25	Radiating pain	4.2	5.00
	Right leg pain	3.5	5.18	Left leg pain	2.9	5.24
	Groin pain	2.9	3.80			
Pain quality	Burning sensation	20.7	**6.34**	Electric shock feeling	18.4	**7.08**
	Sharp / stabbing pain	13.0	5.93	Nerve pain	8.4	5.41
	Burning pain	7.6	5.93	Shooting pains	6.7	5.61
	Stinging	4.9	5.21	Severe pain	4.9	3.08
	Crippling / extreme pain	3.7	5.11			
Pain other	Pain / chronic pain	27.0	3.70	Widespread pain / body aches	3.5	2.73
Motor nerve damage or irritation	Muscle spasms	19.3	**6.64**	Weakness in legs	18.3	**7.01**
	Weakness	12.2	5.01	Foot drop	5.7	5.54
	Neuropathy	5.5	5.38	Leg cramps	5.1	5.23
	Twitching	4.8	5.08	Cramping	4.6	3.14
	Spasms	3.7	3.96	Leg/s spasms	3.4	4.88
Altered sensation	Numbness	30.5	**6.96**	Tingling sensation	18.0	**6.05**
	Numbness in legs	16.4	**7.00**	Formication (feeling of something crawling on you)	15.2	**7.09**
	Tingling legs	7.9	5.50	Pins and needles	5.4	4.79
	Lower leg numbness	4.3	4.74	Water dripping sensation	3.8	5.63
Symptoms in feet	Numbness in feet	17.2	**7.01**	Foot pain	16.6	**6.52**
	Burning sensation in feet	14.4	**7.04**	Tingling feet	6.0	5.06
Bladder or bowel symptoms	Bladder issues (unspecified)	11.9	**7.01**	Incontinence	10.3	5.69
	Bowel issues (unspecified)	6.6	5.20	Fecal incontinence	4.2	5.14
Head and neck symptoms	Headaches	22.3	4.54	Blurred vision	8.0	5.21
	Balance issues / loss of balance	7.5	4.83	Neck pain	6.6	4.37
	Migraines	6.4	3.32	Tinnitus	6.2	4.96
	Dizziness / severe dizziness	4.4	2.32	Brain fog	3.3	2.09
Difficulty with daily activities	Mobility issues / difficulty walking	18.0	5.48	Difficulty standing	9.4	5.82
	Difficulty sitting	7.6	5.61	Pain sitting	3.8	5.44
	Unable to walk / stand	3.0	3.72			
Other	Fatigue	10.9	1.95	Insomnia	4.8	2.54
	Sweating / overheating	4.5	3.55	Depression / feeling depressed	3.9	2.04
	Nausea	3.1	1.72			

n, number of participants who reported symptom data (1101); *STW*, StuffThatWorks

[a] STW cross-condition score (scale 1-10): A score ≥ 6 is highly indicative for arachnoiditis, a score between 3-5 has a medium degree of indication, and a score < 3 has a low indication (see Methods). Scores ≥ 6 are shown in bold

Earliest presenting symptoms

Participants were asked to recall whether, prior to diagnosis or early in the condition, there were any symptoms or warning signs that worried them or made them feel something was not right. The majority of participants (92.2%, n = 1019) endorsed early symptoms, reporting 418 symptoms, similar in character to the general arachnoiditis symptoms participants had listed. Pain and altered sensation were predominant among the most common reported early symptoms (14/20 symptoms). An absence of early symptoms was indicated by 8.8% of respondents. The frequency, percent and STW cross-condition score for the 20 most common early symptoms are presented in Table 3. Supplementary Material 3 provides a complete list of all early symptoms reported by participants, ordered by frequency (n, %, STW cross-condition score).

435 **Table 3. Most common early symptoms among 1019 study participants reporting early**
436 **symptoms**

Early symptom	n	%	STW cross-condition score [a]
Pain / chronic pain	172	16.8	5.40
Back pain	110	10.8	**7.03**
None	90	8.8	-
Legs pain	73	7.1	**7.00**
Lower back pain	51	5.0	**7.00**
Mobility issues / difficulty walking	48	4.7	5.17
Numbness	47	4.6	**6.02**
Numbness in legs	44	4.3	**6.72**
Constant pain	41	4.0	5.26
Severe pain	41	4.0	5.07
Burning sensation	39	3.8	5.79
Weakness in legs / jelly legs	36	3.5	**6.07**
Numbness in feet	34	3.3	**6.16**
Deterioration of health / condition / worsening of symptoms	31	3.0	2.82
Electrical shock feeling	30	2.9	**6.10**
Burning sensation in legs	28	2.7	5.92
Surgery induced condition	28	2.7	5.62
Crippling / extreme pain	27	2.6	5.58
Headaches	27	2.6	3.67
Tingling sensation	26	2.5	5.12

437 *n*, number of participants with each symptom; *STW*, StuffThatWorks.
438 [a] STW cross-condition score (scale 1-10): A score ≥ 6 is highly indicative for arachnoiditis, a score between 3-5 has
439 a medium degree of indication, and a score < 3 has a low indication (see Methods). Scores ≥ 6 are shown in bold.

440

441 ## Assessment of aggravating factors

442 Factors which exacerbated their condition were reported by 95.0% of respondents (n =
443 1050), comprising 276 different aggravating factors. The 20 most frequently reported
444 aggravating factors are presented in Fig. 3. “Sitting or sitting too long” and “standing or
445 standing too long” were the most common aggravating factors, reported by 62.5% and 58.3%
446 of respondents, respectively, and carried the highest cross-condition scores for aggravating
447 factors at 7.70 and 7.59, respectively.

448



Fig. 3 Most common aggravating factors among 1050 study participants reporting aggravating factors. STW (StuffThatWorks) cross-condition score (scale 1-10): A score ≥ 6 is highly indicative for arachnoiditis, a score between 3-5 has a medium degree of indication, and a score < 3 has a low indication (see Methods). Solid bars represent scores ≥ 6.

Analysis revealed 62 exacerbating factors reported by ≥ 1% of participants, stratified into eight discrete categories: positional factors (sitting, standing, or lying down); specific movements or activities; physical exertion intensity; weather or temperature variables; physical or mental health parameters; medical treatment or non-treatment; inactivity; and miscellaneous variables. Table 4 presents these factors by category, including their frequency and STW cross-condition scores. Supplementary Material 4 provides a complete list of all aggravating factors reported by participants, ordered by frequency (n, %, STW cross condition

score).

Table 4. Aggravating factors by category

Categories	Subcategory	Aggravating factors Percent of participants (n=1050); STW cross-condition score [a]					
			%	score		%	score
Positions	Sitting	Sitting or sitting too long	62.5	**7.70**	Car rides / long car rides	3.8	5.04
		Driving	3.8	5.02	Sitting upright	1.6	3.32
	Standing	Standing or standing too long	58.3	**7.59**	Standing still	3.2	5.39
	Lying down	Laying down	7.5	**6.16**	Lying down for long	3.8	5.43
		Lying on back	2.4	4.40	Sleep	1.1	1.56
	General	Being in one position too long	4.5	**6.14**	Certain positions	1.2	2.02
Movements or activities	Walking	Walking	30.6	**7.17**			
	Bending, twisting or stretching	Bending over	22.7	**7.29**	Twisting	5.8	**6.33**
		Stretching	2.4	4.60	Reaching up	1.4	3.81
	Lifting	Lifting	14.2	**7.10**	Heavy lifting	3.5	4.67
		Carrying heavy things	1.1	1.85			
	Transitional movements	Standing up	5.4	**6.54**	Squatting	2.9	5.38
		Stair climbing / going down stairs	1.5	2.61			
	General	Everything / life	3.2	3.57	Certain activities	1.7	1.93
		Housework	1.5	3.36	Cleaning	1.3	2.62
		Gardening	1.0	2.05			
Physical exertion intensity		Walking too much	15.5	**7.08**	Activity / too much activity	12.7	**6.24**
		Excessive movement	10.2	5.76	Physical exertion	10.1	4.73
		Overdoing	7.1	5.61	Physical activity	5.1	4.80
		Exercise	4.1	2.09	Running	2.0	2.95
Weather or temperature		Cold weather	7.5	3.35	Temperature / weather (unspecified)	4.8	3.91
		Weather changes	3.4	4.18	Barometric pressure changes	3.0	4.69
		Heat	2.4	1.65	Humidity	2.2	2.40
		Hot weather	1.5	1.96	Wet weather	1.2	1.85
Physical or mental health parameters		Stress	17.3	1.62	Lack of sleep	3.2	1.49
		Fatigue	2.6	1.70	Pain	2.0	2.86
		Poor sleep	1.2	1.83	Sleep	1.1	1.56
		Falling	1.1	2.42	Anxiety / feeling anxious	1.0	1.22
Medical treatment or non-treatment		Medication (unspecified)	11.8	1.33	Not adhering to treatment	3.4	2.01
		Surgery	1.6	2.84	Lack of treatment	1.1	1.67
Inactivity		Lack of movement	2.8	3.54	Inactivity	2.5	2.43
		Lack of exercise	1.2	1.35			
Miscellaneous		Sugar / too much sugar	2.7	1.61	Menstrual cycle (period)	1.1	1.43
		Alcohol / drinking too much	1.0	1.11	Poor diet	1.0	1.23

n, number of participants who reported aggravating factors (1050); *STW*, StuffThatWorks.

[a] STW cross-condition score (scale 1-10): A score ≥ 6 is highly indicative for arachnoiditis, a score between 3-5 has a medium degree of indication, and a score < 3 has a low indication (see Methods). Scores ≥ 6 are shown in bold.

Assessment of comorbid conditions

Participants were asked to list all diagnosed comorbid medical conditions, with 830 (72.2%) respondents reporting at least one such condition. The 20 most common conditions are shown in Table 5 along with their frequency, % and STW cross-condition score. Eight comorbidities were spine-related in origin, seven of which yielded cross-condition scores highly indicative of arachnoiditis.

Table 5. Most common comorbidities among 830 study participants reporting comorbidities

Comorbidity	n	%	STW cross-condition score [a]
Degenerative Disc Disease (DDD)	268	32.3	**7.13**
Spinal stenosis	210	25.3	**7.33**
Fibromyalgia	207	25.0	3.82
Hypertension	112	13.5	2.10
Osteoarthritis	103	12.4	4.97
Arthritis (unspecified)	99	11.9	5.04
Cauda equina syndrome	91	11.0	**7.52**
Scoliosis	85	10.3	5.86
Clinical depression	84	10.1	1.24
Migraine	83	10.0	2.03
Failed back surgery syndrome (FBSS)	82	9.9	**7.43**
Tarlov cysts	81	9.8	**7.39**
Herniated disc	70	8.4	**7.02**
Hypothyroidism	69	8.3	1.72
Anxiety / generalized anxiety disorder (GAD)	68	8.2	1.15
Ehlers Danlos Syndrome (EDS)	66	8.0	4.09
Diabetes mellitus	56	6.8	2.55
Bulging discs	53	6.4	**7.00**
Complex regional pain syndrome	50	6.0	**6.43**
Rheumatoid arthritis	47	5.7	2.93

n, number of participants with each comorbidity; *STW*, StuffThatWorks

[a] STW cross-condition score (scale 1-10): A score ≥ 6 is highly indicative for arachnoiditis, a score between 3-5 has a medium degree of indication, and a score < 3 has a low indication (see Methods). Scores ≥ 6 are shown in bold

482 ## Survey of treatments

483 The 30 treatments most frequently tried by the 982 participants (88.9%) who responded
484 to this question are shown in Table 6, ordered by self-rated effectiveness (STW estimated
485 ratio). The 90% confidence intervals for rates of effectiveness are generally quite broad,
486 reflecting the relatively small numbers of participants who rated individual treatments as
487 effective.

488 Among the treatments in Table 6, it can be seen that the most frequently tried
489 treatments are not the same as those self-rated as most effective. The most frequently tried
490 treatments (listed by ≥ 20% of respondents) include gabapentin (37.9%), physiotherapy
491 (30.1%), pregabalin (26.5%), and oxycodone (23.5%). In contrast, the treatments with the
492 highest rated effectiveness (≥ 20% estimated ratios) include low-dose naltrexone (28%
493 effective, tried by only 6.8%), ketamine infusion (24.8%), fentanyl (21.1%), and oxycodone
494 (20.9%).

495 **Table 6. Most frequently tried treatments among 982 study participants reporting**
496 **treatment data, ranked by self-rated effectiveness**

Treatment tried	Total [a] n (%)	Self-rated as effective [b]		
		n	STW estimated ratio (%) [c]	90% CI
Naltrexone hydrochloride (low dose naltrexone)	67 (6.8)	20	28.1	20.0-37.0
Ketamine hydrochloride (ketamine infusions)	65 (6.6)	17	24.8	16.9-33.4
Fentanyl (patch and other routes)	92 (9.4)	20	21.1	14.7-28.1
Oxycodone hydrochloride	231 (23.5)	49	20.9	16.8-25.4
Pain relief medication (unspecified)	97 (9.9)	20	20.1	14.0-26.8
Morphine sulfate	104 (10.6)	21	19.7	13.9-26.2
Spinal cord stimulator (SCS)	119 (12.1)	24	19.7	14.2-25.8
Tizanidine hydrochloride	77 (7.8)	15	18.9	12.4-26.3
Hydrocodone bitartrate	72 (7.3)	12	16.3	10.1-23.5
Stretching	72 (7.3)	11	15.1	9.0-22.1
Magnesium (glycinate and others)	67 (6.8)	10	14.7	8.6-21.9
Paracetamol + oxycodone hydrochloride	64 (6.5)	9	14.0	7.9-21.2
Pregabalin	260 (26.5)	36	13.8	10.5-17.4
Tramadol hydrochloride	109 (11.1)	14	12.9	8.2-18.3
Cannabidiol (CBD)	79 (8.04)	10	12.7	7.4-19.0
Muscle relaxants	65 (6.5)	8	12.4	6.7-19.2
Hydrotherapy	76 (7.7)	9	12.0	6.7-18.2
Massage	94 (9.6)	11	11.8	7.0-17.4
Chiropractic	65 (6.6)	7	11.0	5.7-17.6
Paracetamol + hydrocodone bitartrate	68 (6.9%)	7	10.6	5.4-16.9
Duloxetine hydrochloride	135 (13.7)	14	10.5	6.6-15.0
Baclofen / baclofen intrathecal pump	92 (9.4)	9	10.0	5.6-15.4
Gabapentin	372 (37.9)	37	10.0	7.6-12.7
Turmeric capsules / pills	74 (7.5)	7	9.8	5.0-15.7
Paracetamol (acetaminophen)	76 (7.7)	6	8.4	4.0-13.8
Physiotherapy	296 (30.1)	21	7.2	5.0-9.8
Amitriptyline hydrochloride	81 (8.2)	5	6.8	3.0-11.6
Ibuprofen	88 (9.0)	4	5.2	2.1-9.4
Transcutaneous electrical nerve stimulation	85 (8.7)	3	4.3	1.5-8.2
Acupuncture	90 (9.2)	2	3.1	0.9-6.4

497 *n*, number of participants reporting each treatment; *STW*, StuffThatWorks; *CI*, confidence intervals
498 [a] Tried treatments were 90% normalized by the STW normalization tool (see Methods)
499 [b] Self-rated effectiveness = "significant improvement of condition"
500 [c] STW estimated ratio = binomial proportion with 90% confidence intervals (see Methods)

501

502 The 30 treatments rated as most detrimental by participants are shown in Table 7. The
503 most detrimental (≥ 20% estimated ratios) are: epidural steroid injections (38.5%), spinal
504 injections (unspecified) (31.1%), myelogram (28.5%), epidural injections (unspecified) (28.2%),
505 surgery (21.7%), and traction (20.4%).

506 **Table 7. Most detrimental treatments among 982 study participants reporting treatment**
507 **data, ranked by self-rated detriment**

Treatment tried	Total [a] n (%)	Self-rated detriment [b]		
		n	STW estimated ratio (%) [c]	90% CI
Epidural steroid injections	37 (3.8)	20	38.5	28.0-49.5
Spinal injections (unspecified)	21 (2.1)	11	31.1	19.6-43.8
Myelogram	7 (0.7)	6	28.5	14.9-44.2
Epidural injections (unspecified)	64 (6.5)	22	28.2	20.4-36.6
Surgery (unspecified)	24 (2.4)	8	21.7	12.1-32.8
Traction	7 (0.7)	4	20.4	8.8-34.8
Recurrent surgeries	10 (1.0)	4	18.1	7.7-31.2
Caudal epidural injection	6 (0.6)	3	17.0	6.3-30.9
Hydrocortisone, incl. cortisone injections	21 (2.1)	5	15.6	7.2-26.0
Spinal cord stimulator (SCS) implant	28 (2.9)	6	15.4	7.6-24.9
Nerve blocks (unspecified)	22 (2.2)	5	15.2	7.0-25.4
Facet joint injection	19 (1.9)	4	13.7	5.7-23.9
Fentanyl (patch and other routes)	91 (9.3)	12	12.0	7.3-17.4
Spinal cord stimulator (SCS)	119 (12.1)	15	11.7	7.5-16.5
Physiotherapy	297 (30.2)	35	11.4	8.6-14.5
Gabapentin	372 (37.9)	37	9.8	7.4-12.3
Chiropractic	66 (6.7)	7	9.6	4.9-15.3
Pregabalin	292 (26.7)	25	9.3	6.6-12.3
Methadone	36(3.7)	4	9.3	3.8-16.6
Opioids (unspecified)	63 (6.4)	6	8.7	4.2-14.3
Corticosteroids (unspecified), including steroid injections (unspecified)	54 (5.5)	5	8.4	3.8-14.3
Amitriptyline	82 (8.3)	7	8.0	4.1-12.9
Morphine sulfate	104 (10.6)	8	7.4	3.9-11.7
Muscle relaxants	66 (6.7)	5	7.2	3.2-12.3
Duloxetine hydrochloride	136 (13.8)	9	6.5	3.6-10.1
Ketamine hydrochloride (ketamine infusions)	65 (6.6)	4	6.1	2.4-10.9
Naltrexone hydrochloride (low-dose naltrexone)	68 (6.9)	4	5.8	2.4-10.5
Acupuncture	91 (9.3)	4	4.6	1.8-8.3
Pain relief medications (unspecified)	97 (9.9)	4	4.4	1.8-7.9
Oxycodone hydrochloride	230 (23.4)	3	2.0	0.8-3.7

508 *n*, number of participants reporting each treatment; *STW*, StuffThatWorks; *CI*, confidence intervals
509 [a] Tried treatments were 90% normalized by the STW normalization tool (see Methods)
510 [b] Self-rated detriment = "significant worsening of condition"
511 [c] STW estimated ratio = binomial proportion with 90% confidence intervals (see Methods)

512

513 Comparing Tables 6 and 7, it is evident that for several of the interventions that appear
514 on both lists, reports of an effective versus detrimental effect registered similar numbers. For
515 example, 37 respondents reported that gabapentin was effective, while an equal number

516 reported that it was detrimental.

517

518 Discussion

519 This preliminary investigation represents the most comprehensive observational cross-
520 sectional study of arachnoiditis documented to date and establishes the foundation for
521 subsequent analytical frameworks. The patient-centered methodological approach enabled
522 the assembly of a substantially larger cohort than conventional methods would allow. Our
523 research not only consolidates what is already known about arachnoiditis but also presents
524 several new findings.

525

526 Prevalence according to demographics

527 Female participants comprised 75.9% of respondents in our study. This compares with
528 45.5% in a 2024 systematic review of 147 studies (510 cases) [7], suggesting a more balanced
529 sex distribution in the broader literature. Other large (n ≥ 80) case series not covered in the
530 systematic review have shown variable sex distributions, with female proportions ranging from
531 33% to 81% [4,12,28,34].

532 The true incidence of arachnoiditis and its sex ratio have not been well defined and may
533 depend on causal factors, highlighting a need for further epidemiological studies. The marked
534 female predominance seen in our study may reflect multiple factors. Autoimmunity may play a
535 role in the pathophysiology of arachnoiditis, and the majority of autoimmune conditions are
536 more common in females [90,91]. Another risk factor specific to females is obstetric epidural

537 anesthesia. When carried out properly, epidural anesthesia is an extremely rare cause of
538 arachnoiditis [30,92,93] however as up to two-thirds of females in developed countries
539 undergo this procedure during childbirth [94], the sheer volume of cases augments the
540 prevalence of this complication in proportion to the substantial number of procedures
541 performed. It is also possible that one of the contributors to sex ratio imbalance in our study
542 could be related to participation on the STW platform facilitated through social networks, in
543 which females tend to be more engaged [95,96], although participants joined through multiple
544 pathways.

545 In terms of age distribution, 73.1% of our respondents were ≥ 46 years old, which is
546 older than the mean age of 44.2 years (standard deviation [SD] 17.53) reported in the 2024
547 systematic review [7]. This difference likely reflects our cross-sectional design, which captures
548 individuals with established arachnoiditis rather than those at initial diagnosis. However, our
549 participants' ages fall within the SD of the review findings [7], and align with the
550 aforementioned case series, which report median or mean ages of 48.4 to 61.3 years
551 [4,12,28,34]. Importantly, our work adds insight as to the age of initial symptom onset, which is
552 spread across earlier age groups, with 53.6% ≤ 45 years.

553

554 Symptoms of arachnoiditis

555 The arachnoiditis symptoms we report are consistent with previous studies
556 [1,4,10,12,34], however, our work further elaborates symptom descriptions, and also identifies
557 which symptoms are most indicative of the condition. Pain and sensory disturbances were
558 predominant among the most frequently reported symptoms (35/71 symptoms), and included

559 burning sensations, electric shock sensations, shooting pain, numbness, tingling, and
560 formication (sensations of insects crawling on the skin). All these symptoms had high STW
561 cross-conditions scores, suggesting greater specificity for arachnoiditis. Formication has been
562 described in previous reports [12,34] although it is not unique to arachnoiditis, and has also
563 been reported with other neurological conditions [97]. Aldrete [12] has proposed
564 neurophysiological explanations for many of the sensory symptoms in arachnoiditis, including
565 formication, and also described pain distribution patterns that may not always follow nerve
566 dermatomes but may be more regional or patchy in nature, reminiscent of findings in tethered
567 cord syndrome [98,99].

568 Beyond sensory symptoms, signs of motor nerve damage or irritation are also
569 frequently reported in our study, including weakness, foot drop, muscle spasms, cramps and
570 twitching. Muscle related symptoms such as spasms, cramps and fasciculations have been
571 previously reported [1,12] however they lack detailed characterization in the literature,
572 warranting more comprehensive study to better understand their pathophysiology, temporal
573 progression and their relationship to the location of spinal cord involvement. Motor symptoms
574 suggest that electrodiagnostic tests may be useful, however, it has been noted that such tests
575 do not produce a consistent pattern that can be identified as arachnoiditis for diagnostic
576 purposes [3,4,12]. Yet, the potential utility of these tests has not been systematically
577 investigated in individuals with arachnoiditis, particularly among those with a spectrum of
578 motor nerve dysfunction, as has been studied in related conditions, such as adult tethered
579 cord [100], syringomyelia [101], and Tarlov cysts [102,103]. Such research could prove
580 beneficial for diagnosis, especially in suspected cases, as well as for monitoring disease
581 progression.

582 An array of other physical signs and symptoms were described in people living with
583 arachnoiditis in our cohort. Symptoms localized to the feet were common, with 17.2%
584 reporting numbness, 16.6% pain, and 14.4% burning sensation, all of which were associated
585 with high STW cross-condition scores ≥ 6. Exclusion of the more common causes of sensory
586 dysesthesias in the feet seen in other conditions, along with the presence of other
587 characteristic findings and risk factors consistent with arachnoiditis, may lead to more
588 accurate diagnosis and shorten time to diagnosis.
589 Eight diverse types of head and neck symptoms were reported by study participants, led
590 by headache (22.3%), however none produced a STW cross-condition score indicating a high
591 specificity for arachnoiditis. Bladder and bowel symptoms, led by "unspecified bladder issues"
592 (11.9%) and incontinence (10.3%), have also been reported in many previous studies
593 [1,12,34,47] with only "unspecified bladder symptoms" producing a cross-condition score ≥ 6.
594

595 Earliest presenting symptoms

596 We sought to characterize the earliest presenting symptoms of arachnoiditis given there
597 is some evidence that disease progression might be arrested or reversed in some individuals
598 with early intervention. Early recognition may also provide patients with timely explanations for
599 their symptoms and help to reduce diagnostic uncertainty. Our preliminary results suggest that
600 the character and pattern of earliest symptoms do not differ significantly from general reported
601 symptoms. Pain and altered sensation predominated among the top 20 earliest symptoms.
602 Future studies will benefit from gathering information about initial symptoms as soon as

603 possible after diagnosis to gain a more accurate picture of symptom development.

604

605 ## Nature of aggravating factors

606 The most frequently reported aggravating factors, “sitting or sitting too long” and
607 “standing or standing too long”, were reported by 62.5% and 58.3% of the study population,
608 respectively. The positional nature of these and other commonly reported aggravating factors
609 is noteworthy, both in our study and in previous reports. Porcelli and Tennant [34] reported that
610 87.5% of their 80 subjects with lumbosacral arachnoiditis experienced relief of symptoms
611 upon standing up, 86.3% reported that standing up for too long caused the need to lie down,
612 and 83.8% of their subjects found that it hurt to lie flat on their back. Similar positional
613 symptoms have been documented in case reports of arachnoiditis [18,104,105]. The specific
614 positions that aggravate symptoms may be correlated with the spinal levels that are affected
615 by arachnoiditis (not assessed in this study), such that the inflamed or adhered nerves are
616 compressed or stretched in certain positions. In tethered cord syndrome, positional symptoms
617 caused by elongation of the lumbar spine have been reported [98], and a potentially analogous
618 mechanism may be relevant in some cases of arachnoiditis. Positional aggravating factors may
619 also be reflective of their effect in increasing CSF pressure in various parts of the spine against
620 an arachnoiditis-induced CSF flow disturbance, or they may be suggestive of a particular
621 complication. In future studies, we intend to correlate the level of spinal involvement with
622 specific aggravating factors.

623 Movements that provoked symptoms were categorized as walking, lifting, transitional
624 movements, and activities that bend, twist or stretch. Symptom exacerbation likely involves

625 multifactorial mechanisms. For example, when a nerve is inflamed or irritated, it becomes
626 more sensitive to mechanical forces like stretching or compression [106]. Additionally, in
627 disease conditions causing mechanical nerve compromise such as tethered cord syndrome or
628 radiculopathy, stretching of nerve roots contributes to pathophysiology due to limitation in
629 nerve root movement or temporary ischemic changes [50,107,108], a finding which has been
630 extended to arachnoiditis [50].

631 Activities related to lifting may involve additional mechanisms. During lifting the core
632 abdominal muscles are activated, and in heavy lifting a Valsalva maneuver may also occur.
633 These muscle activations increase intra-abdominal and intra-thoracic pressure transiently
634 [109], both of which increase CSF pressure or volume [110–113]. Such changes can alter CSF
635 flow in individuals with arachnoiditis or increase pressure against the nerve roots, potentially
636 exacerbating neurologic symptoms. Increases in CSF pressure have been associated with
637 symptom exacerbation in individuals with related spinal conditions including syringomyelia
638 [114] and Tarlov cysts [103]. Patients with syringomyelia are generally advised to avoid
639 deadlifts, as the Valsalva maneuver can result in deleterious syrinx expansion [114].

640 Spinal comorbidities, which were common among study participants, present
641 additional complexities when interpreting aggravating factors, as they may share some
642 positional and movement-related triggers.

643 Intense physical exertion commonly caused exacerbation of symptoms. While research
644 shows benefits of physical activity for chronic or neuropathic pain [115–118], low or low-
645 moderate intensity exercise is typically recommended—aligning with our findings. Individually
646 tailored recommendations for physical activity and activity modification in individuals with
647 arachnoiditis are generally advised.

Some aggravating factors described in our study, while commonly reported, showed low STW cross-condition scores and can be seen across multiple conditions besides arachnoiditis. These factors include variations in the weather or temperature, poor sleep, stress, anxiety, and lack of movement.

Our analysis has the potential to facilitate the development of broader and more precise clinical diagnostic criteria for arachnoiditis based on symptoms and aggravating factors, improving diagnostic accuracy and differential diagnosis. This would be especially important for those in whom arachnoiditis is suspected, but there are no correlative signs evident in radiological studies. Furthermore, reducing or avoiding exposure to an individual's known aggravating factors has practical relevance for symptom management. Since neuropathic pain in individuals with arachnoiditis is often delayed in onset and protracted in duration relative to the inciting activity [1] the empiric pacing of known aggravating activities requires anticipation to avoid triggering symptom flares.

Comorbid conditions

Coexisting degenerative spine conditions or anatomic abnormalities are frequently listed as comorbidities in our study, including spinal stenosis, cauda equina syndrome, scoliosis, and disc-related pathologies such as degenerative disc disease, or herniated or bulging discs. All of these conditions, except scoliosis, had high STW cross-condition scores, suggesting they correlate strongly with arachnoiditis. While these conditions have been associated with lumbar arachnoiditis in many earlier reports [4,7,12,14,28], they also lead to invasive spinal interventions—a well described risk factor that is often concomitantly reported

670 in arachnoiditis studies (not ascertained in this study). However, both disc pathology [29,104]
671 and degenerative spinal conditions [28,39,49,119,120] have also been identified as the sole
672 apparent risk factor in cases of arachnoiditis with no history of spinal interventions.

673 In a related finding, Parenti et al. [43] demonstrated that spinal comorbidities in lumbar
674 arachnoiditis have a significant relationship to arachnoiditis symptom dynamics, suggesting
675 that integrated treatment of these comorbidities may help mitigate symptom progression.
676 However, treatment decisions must carefully consider the potential for invasive interventions
677 to worsen arachnoiditis. Although Palackdharry et al. [1] reported finding no evidence that
678 surgical procedures (or lumbar puncture) in unaffected adjacent spinal levels worsen existing
679 arachnoiditis, this was reported without detail. Further studies are required.

680 Failed back surgery syndrome was listed by 10% of our study participants as a
681 comorbidity, consistent with previous studies [1,12,14,121]. Failed back surgery syndrome is
682 an umbrella term for a variety of pathological conditions, including arachnoiditis, that result in
683 persistent symptoms after spine surgery. The extent to which symptomatic lumbosacral
684 arachnoiditis may be present prior to spinal surgery is unknown. This may be difficult to
685 ascertain due to the overlap of symptoms between arachnoiditis and the underlying pathology
686 necessitating surgery. In their study of patients undergoing surgery for spinal stenosis—a
687 condition that is both a known cause of arachnoiditis due to mechanical irritation and creates
688 confounding radiological findings due to the narrowed spinal canal [119,120,122]—Kawauchi
689 et al. performed pre-operative myeloscopic assessment of the subarachnoid space [71]. They
690 found that all patients demonstrated some degree of pre-operative arachnoid adhesions,
691 however those with marked pre-operative adhesions experienced worse outcomes after the
692 spinal stenosis surgery. Where surgeons are interested in determining if arachnoiditis is

693 present pre-operatively and radiological findings are ambiguous, the expanded symptoms list
694 may assist, particularly when patients report additional symptoms more suggestive of
695 arachnoiditis (for example, burning sensations in the feet, or formication) than those typically
696 associated with their degenerative condition.

697 Our study revealed a 9.8% prevalence of Tarlov cysts in our sample, approximately
698 twice the estimated prevalence in the general population [123], supporting the association of
699 Tarlov cysts with arachnoiditis proposed in previous reports [34,37,38]. A further 8.0% of
700 respondents reported a diagnosis of EDS, which is higher than the estimated prevalence of
701 joint hypermobility spectrum disorders in the general population (3-4%), and considerably
702 higher than typical rates of EDS [124], consistent with this association in earlier reports
703 [34,35]. This association, however, was not explicitly noted in a 2017 comprehensive review of
704 the neurological and spinal manifestations of EDS [125], suggesting it may be
705 underrecognized. Fibromyalgia was reported as a comorbidity in 25.0% of study participants,
706 but produced a low STW cross-condition score. Given that fibromyalgia is a diagnosis of
707 exclusion, with some symptoms overlapping those attributed to arachnoiditis, fibromyalgia
708 could be misdiagnosed in patients with arachnoiditis. However, fibromyalgia demonstrates
709 similarly high comorbid rates across various chronic conditions, including inflammatory
710 arthritis, autoimmune disorders, centralized pain syndromes and neurological diseases, where
711 it typically adversely affects quality of life and health status in these individuals [126]. The
712 substantial prevalence of fibromyalgia in our cohort suggests it may represent a genuine and
713 clinically important comorbidity in arachnoiditis patients.

714 Depression and anxiety, commonly associated with chronic pain conditions, were also
715 frequently reported as comorbidities in our study. Even though osteoarthritis, reported by

716 12.4% of respondents, is highly prevalent in the age-related general population and less
717 indicative of arachnoiditis according to a low cross-condition score, it should be noted that
718 people with arachnoiditis and syrinx may experience Charcot-type neuropathic arthropathy in
719 a variety of joints [127]. Hypertension, another comorbidity with a low cross-condition score, is
720 also prevalent in the general population. However, episodic or paroxysmal surges of severe
721 hypertension may be a sign of autonomic dysreflexia in individuals with arachnoiditis or syrinx
722 [65,128,129]. In future studies, gathering more detailed information regarding comorbidities
723 will elucidate etiological factors and predisposing conditions.
724

725 Tried treatments

726 Participants in our study attempted a wide range of treatments, including
727 pharmaceutical analgesics and neuropathic pain-directed medications, muscle relaxants,
728 interventional pain procedures, over-the-counter pain relievers, cannabinoids, natural
729 supplements, bio-electrical stimulation treatments, off-label treatments, and physical
730 therapies. This range highlights that current approaches are predominantly focused on
731 symptom management rather than addressing underlying inflammatory or disease-modifying
732 mechanisms.
733 Confirming the consensus from earlier literature reports [1,3,11,12], our study
734 demonstrates that arachnoiditis remains challenging to treat. Participant-reported treatment
735 effectiveness rates ranged from 3.1% to 28.1%, with most treatments showing less than 15%
736 effectiveness, demonstrating the critical need for developing more effective treatment
737 strategies for this condition. Importantly, the wide confidence intervals for effectiveness

738 indicate considerable uncertainty in these estimates, meaning the true rates could be much
739 lower or higher.

740 Among the treatments, it is notable that the most frequently tried treatments are not the
741 same as those rated as most effective. The most commonly tried treatments—gabapentin
742 (37.9% of participants), physiotherapy (30.1%), and pregabalin (26.5%)—showed relatively
743 modest effectiveness rates of 10.0%, 7.2%, and 13.8%, respectively. This pattern likely reflects
744 standard clinical practice, where these treatments are commonly prescribed as first-line
745 therapies for neuropathic pain due to their established use and familiarity among clinicians. In
746 contrast, several less frequently used treatments demonstrated higher effectiveness rates.

747 Low dose naltrexone emerged as the most effective participant-reported treatment
748 (28.1% effectiveness) while being tried by only 6.8% of participants. Several recent reports
749 propose naltrexone as a treatment option for arachnoiditis [1,11,34], however there has been
750 an absence of studies evaluating it in arachnoiditis patients. The preliminary data from our
751 study suggests that naltrexone offers beneficial effects, with few detrimental reports, making it
752 an attractive candidate for further study.

753 Ketamine also showed high participant-reported effectiveness rates (24.8%) while being
754 tried by only 6.6% of participants. Its limited use likely reflects significant practical constraints,
755 including controlled substance regulations, requirements for specialized infusion facilities,
756 and notable side effects. Many of the highest-rated treatments face similar implementation
757 challenges. These constraints highlight the broader challenge in chronic pain management of
758 balancing therapeutic efficacy with safety and regulatory concerns.

759 Spinal cord stimulators (SCS) showed a moderate participant-reported effectiveness
760 rate of 19.7%, placing them among the more effective treatments within our study. However, a

761 considerable proportion (11.7%) of individuals who reported using this modality also rated SCS
762 as detrimental. SCS have been recommended as a treatment modality option for arachnoiditis
763 [1], although it has been noted that higher effectiveness rates are typically observed among
764 specially selected patient subgroups. Further investigation into the specific factors
765 contributing to treatment detriment in individuals with arachnoiditis, including patient
766 selection criteria and optimal timing of intervention, will be important for future research.
767 While non-pharmacologic therapies such as stretching, hydrotherapy, and massage
768 showed only modest effectiveness rates in our study (15.1%, 12.0%, and 11.8%, respectively),
769 their favorable safety profiles make them important considerations for patient care,
770 particularly as components of multimodal treatment approaches. Importantly, our findings
771 from the assessment of aggravating factors indicate that certain physical activities, including
772 stretching and overexertion, can worsen symptoms in some patients. Therefore, careful
773 monitoring and gradual, individualized implementation of these therapies is essential.
774 Beyond the commonly reported treatments in our results, many other medications and
775 interventions that have been identified as potentially beneficial in recent arachnoiditis papers
776 were not represented in sufficient numbers in our study population to appear in our results.
777 These include, but are not limited to, ketorolac [34], diclofenac and other non-steroidal anti-
778 inflammatories [3,65], corticosteroids [11,34,104,130], electrotherapeutic agents [65],
779 metformin [1], cerebrolysin [1], eicosapentaenoic acid (fish oil) [104], newer formulations of
780 curcumins [1,65], cognitive behavioral therapy to help modulate pain perception [3], and
781 neural mobilization [1,105]. Similarly, many authors recommend multimodal and
782 interprofessional pain management strategies, however there were not any multi-drug
783 regimens or combination therapies reported with sufficient frequency to appear in our results.

Notably, the prevalence of corticosteroid use may be underestimated in our sample as a consequence of steroid medications being listed individually (e.g., dexamethasone, methylprednisolone) and therefore counted individually rather than as a collective category. Further, the open-text survey questions did not differentiate between treatments for routine daily symptom management versus periodic symptom flares. Since corticosteroids are frequently used to treat symptom flares and reduce inflammation [11,34,65,130], participants may have considered only their routine treatments when responding.

Analysis of data comparing treatments rated as effective versus detrimental revealed a paradoxical pattern wherein certain interventions received contradictory evaluations from different respondents. This may reflect inter-individual physiological differences, variations in disease severity or stage at the time of treatment, therapeutic efficacy that diminishes over time, or differences in underlying etiology. Different causes may elicit distinct inflammatory patterns or therapeutic windows. In the current study, however, we were unable to compare the efficacy of treatments over time or across different etiologies.

The most detrimental treatments in our study primarily consisted of invasive spinal interventions, reflecting their shared capacity to induce spinal cord irritation and inflammation directly though physical or mechanical trauma to already compromised neural tissues. This finding aligns with existing literature [1] that identifies invasive spinal procedures as risk factors for arachnoiditis development.

Contribution of artificial intelligence (AI)/machine learning

Natural language processing techniques, coupled with artificial intelligence and machine learning algorithms, facilitate the analysis of extensive datasets, and have the potential to generate valuable and unique insights. The findings from our study offer considerable new details about arachnoiditis and would not have been feasible without an international online platform and the novel AI tools employed. The STW cross-condition score is particularly unique in its ability to compare individual symptoms, comorbidities and aggravating factors across very large numbers of people with and without arachnoiditis on the online platform, with each receiving a score indicating its specificity for the condition.

AI-generated data output, however, requires careful review and interpretation. For example, in the present study, some similar or identical symptoms were tabulated by AI machine learning as separate entities, such as “tingling” and “pins and needles”. This may have resulted from an incomplete ability of natural language processing to detect various open-label text terms as being synonymous. Further training of AI may be required to better recognize and properly categorize and group terms. Use of AI and machine learning to process and categorize large datasets and images in future studies may help to further establish accurate diagnostic criteria for arachnoiditis, including improved MRI interpretation [131,132].

Study limitations

The most notable study limitations include reliance on self-reported data with a potential for recall bias. Furthermore, while the use of open-text survey questions enables a wide range of responses to facilitate learning as much as possible about the condition in an

826 unbiased manner, this approach may be associated with more unintentional omissions
827 compared to selecting options from a checklist.
828 This study did not address the duration, frequency and severity of symptoms, including
829 symptom flares, and therefore cannot provide an overview of how pain and other symptom
830 patterns differ between participants. In addition, the aggregate nature of the data provided,
831 combined with the absence of data on disease location, extent, or suspected causes,
832 prevented analysis by these variables, which may have yielded valuable insights.
833 As a cross-sectional study, our data on treatment effectiveness do not offer the same
834 level of evidence as controlled clinical trials, and the binary effectiveness measure (self-
835 reported significant improvement of condition) may underestimate treatments that provide
836 modest but clinically relevant symptom relief. However, our aggregated findings may reveal
837 meaningful trends and identify treatments suitable for future studies or individual trials.
838 Assessment of treatment effectiveness is also complicated by the poorly defined natural
839 history of arachnoiditis, often punctuated by symptom flares, and in which some individuals
840 experience disease progression, whereas others remain static [2,4]. Treatments that
841 successfully prevent deterioration rather than provide improvement may represent meaningful
842 clinical success in some patients but may not be assessed as such. In addition, given that our
843 results revealed a wide variety of treatments being used, a further limitation is that our data for
844 effectiveness is limited to the 30 most frequently reported treatments. As a consequence, less
845 frequently used but potentially more effective treatments may not have been captured.
846 Specific adverse events or detrimental responses that might have led to discontinuation of a
847 given treatment were beyond the scope of this present study, as were questions that could link

848 specific treatments or sequencing of treatments to the early or advanced stage of disease for
849 an individual.

850 Generalizability of our findings may be limited given that participation on the STW
851 platform was driven in part by social media engagement, which tends to favor females and
852 those with higher socioeconomic backgrounds [133]. In a similar vein, the majority of our
853 respondents were of white/European ethnicity, which may be related to the survey being
854 available only in the English language, or potentially also to the lower rates of social media
855 involvement among other ethnic groups [134]. Similarly, completion of online questionnaires
856 requires digital literacy and stamina, which could prevent those with significant disability
857 levels from responding. Despite the potential for selection bias and lack of full representation
858 of the entire population of those living with arachnoiditis, our findings remain consistent with
859 earlier reports.

860

861 Future directions

862 Significant areas of unmet need include consensus development of diagnostic criteria
863 to reduce delays in diagnosis, establishment of natural history studies to better delineate
864 differences between individuals in initiation and progression of disease, and discovery and
865 development of more effective treatments.

866 Greater awareness of arachnoiditis and its causes, along with the development of more
867 explicit diagnostic criteria, will aid in accelerating diagnosis and reducing the diagnostic
868 "odyssey" so common in rare diseases [135,136]. Such enhanced recognition by the broader
869 medical community, and improved understanding of the complications, can bring about a

870 three-fold benefit. First, to highlight the essential need for multi-disciplinary care; second, to
871 stimulate pharmaceutical industry and stakeholder interest in initiating and funding
872 therapeutic research; and third, importantly, to benefit those individuals living with
873 arachnoiditis who are actively seeking care, to be heard and understood by health care
874 providers. With more information and training, providers may be less likely to be dismissive of
875 persons affected by the condition, whose disabling symptoms frequently remain externally
876 invisible to others, or to misattribute these symptoms to mental health issues or drug-seeking
877 behavior [1,12,137–139].

878 The development of novel, more effective treatments for arachnoiditis must be a high
879 priority as the science and understanding of modulating neuropathic and centrally mediated
880 pain advance [73]. Given the inflammatory origin of arachnoiditis, future studies might explore
881 whether medications that target inflammation and effectively cross the blood-brain barrier
882 might both relieve symptoms and modify disease progression [1,16,73,140]. Treatments that
883 prevent, stop or reverse fibrotic transformation and its consequences should be a high priority
884 [1]. Advancements in minimally invasive spinal surgery are promising and may offer new
885 treatment avenues for arachnoiditis patients in the future, with reduced morbidity [1]. The
886 development of validated quality-of-life measures specifically designed for assessing
887 interventions, like those recently developed for Tarlov cyst surgery [141], would significantly
888 enhance our ability to measure treatment outcomes.

889 Research should focus not only on developing more effective therapies, but also on
890 identifying biomarkers or clinical predictors that can guide personalized treatment selection,
891 particularly given the potential timing-dependent efficacy of some treatments, and the
892 substantial inter-individual variation in treatment responses observed in our study. In one

893 example of such translational research, Zhang et al. [16] recently delineated differential gene
894 expression from multiple cell types in human arachnoid tissues obtained from patients with
895 and without arachnoiditis undergoing neurosurgery for Chiari malformation or syringomyelia.
896 They employed transcriptome profiling using sn-RNA seq analysis, providing an avenue of
897 discovery for new insights into the pathophysiology and signaling pathways characterizing
898 adhesive arachnoiditis, with the possibility of biomarker discovery.
899 To support such research endeavors, an arachnoiditis international patient registry
900 would enable comprehensive data collection across diverse populations over time and
901 facilitate cross-disciplinary research collaboration. Such a registry could inform future
902 prospective study design by employing a relational database in which sequential treatments
903 are linked with clinical disease stage and treatment outcomes. Quantification of treatment
904 effects can be accomplished through incorporation of validated patient reported outcome
905 instruments evaluating quality of life, pain, disability, and health-related economic costs. It
906 would be advantageous to store select anonymized patient health data such as MRI, EMG and
907 other reports to confirm diagnosis, clarify clinical findings and elaborate upon patient
908 generated data. Serial collection of longitudinal data on symptoms and level of disability would
909 help to better define the natural history of progression in our sample. This would also permit
910 interrogation of the larger dataset to explore any correlations that may exist between the
911 presumptive inciting causes of an individual's arachnoiditis, the disease distribution within the
912 spinal cord, and the stage and severity of the condition. Such an approach might also enable
913 exploration of whether certain subsets of patients respond differentially to various treatments
914 or experience different rates of disease progression.
915

Conclusion

This report describes the largest reported observational study on arachnoiditis to date. Our findings consolidate existing knowledge about the condition while advancing new and important observations regarding age of first symptom onset, range of symptoms, aggravating factors, comorbid conditions and self-assessment of tried treatments. Through the application of novel AI/machine learning algorithms we generated unique insights into symptom profiles, treatment patterns and diagnostic indicators for arachnoiditis, offering clinicians practical tools to improve diagnosis and management.

This work establishes a novel methodological approach to assembling a large patient cohort for rare disease research—a substantially larger cohort than would be possible through conventional methods. This advocacy-enabled, patient-centered model illustrates how rare disease advocacy networks can enable the large-scale data collection necessary for meaningful discovery in a condition that remains understudied and underdiagnosed.

Supplementary Information

Supplementary Material 1. The StuffThatWorks (STW) survey questions used for the data collection for this analysis (PDF file).

Supplementary Material 2. A complete list of all symptoms reported by study participants, ordered by frequency (XLXS file). Includes frequency (n), percent, and STW cross-condition scores.

Supplementary Material 3. A complete list of all early symptoms reported by study participants, ordered by frequency (XLXS file). It includes frequency (n), percent, and STW cross-condition scores.

Supplementary Material 4. A complete list of all aggravating factors reported by study participants, ordered by frequency (XLXS file). It includes frequency (n), percent, and STW cross-condition scores.

Abbreviations

ACMCRN	Arachnoiditis and Chronic Meningitis Collaborative Research Network
AI	Artificial intelligence
CSF	Cerebrospinal fluid
EDS	Ehlers Danlos Syndrome
MRI	Magnetic resonance imaging
SCS	Spinal cord stimulator
STW	StuffThatWorks

Declarations

Ethics approval and consent to participate

This study involved secondary analysis of de-identified, aggregated data from the StuffThatWorks digital health platform. The use of these data for research was approved by the

Helsinki/ Ethics Committee at Sheba Medical Center, Israel (protocol #7356-20-SMC). Before sharing any data, all participants provided digital consent upon platform registration by agreeing to the platform's terms of use and privacy policy, which informed them that their de-identified data may be used for research purposes, including by external researchers. The approving ethics committee deemed this prospective consent adequate and approved a waiver of requirement for additional consent for use of data from its medical questionnaire for research purposes, further stipulating that any data shared with external researchers must be in aggregate form only. Further details are provided in the Methods section.

Consent for publication

Not applicable. The manuscript does not contain any identifiable individual data.

Availability of data and materials

All aggregated data generated or analyzed during this study are included in this published article and its supplementary information files.

Competing interests

NM participates on the Medical Advisory Board for StuffThatWorks. ED was employed by StuffThatWorks at the time of this study and was responsible for data extraction. The remaining authors declare that they have no competing interests.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contributions

Conceptualization: LV, NM, MB, PG, LB. Data curation: ED, MB, SS, LB. Formal analysis: ED, MB, IS, LB. Investigation: LV, ED, PG. Methodology: LV, NM, ED, MB, LB. Resources: LV, DRB, SS. Supervision: LV, LB. Visualization: NM, MB, DRB, SS, LB. Writing – original draft: MB, LB, NM, RS. Writing – review & editing: LV, NM, ED, RS, MB, PG, DRB, SS, LB. All authors have read and approved the final manuscript.

Acknowledgements

The authors wish to thank all the individuals living with arachnoiditis who participated on the STW platform. We acknowledge StuffThatWorks Ltd for use of their digital platform, data aggregation and insights generation. We are grateful to Eve Blackburn for her efforts in raising awareness of the STW platform among individuals with arachnoiditis. We thank Michele Hansen PhD MPH and Richard Dobson MD for reviewing the manuscript, and Rob Lloyd PhD for his review of the CSF dynamics content. We are grateful to Enoch Carter for assistance with data preparation. We appreciate the continuing graphic design support of Matthew Churchward and Eve Blackburn. We dedicate this paper to the memory of ACMCRN co-founder and former VP of Research, Terri Lewis, PhD.

Authors' information

[1] Arachnoiditis and Chronic Meningitis Collaborative Research Network (ACMCRN), London, Ontario, Canada

[2] Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel

[3] Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Ramat Gan, Israel

[4] StuffThatWorks Ltd, Tel Aviv, Israel

[5] Department of Neurology, Sheba Medical Center, Ramat Gan, Israel

[6] Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada

References

[1] Palackdkharry CS, Wottrich S, Dienes E, Bydon M, Steinmetz MP, Traynelis VC. The leptomeninges as a critical organ for normal CNS development and function: first patient and public involved systematic review of arachnoiditis (chronic meningitis). PLOS One 2022;19. doi: 10.1371/journal.pone.0274634. PMID: 36178925.

[2] Mastorakos P, Jonathan Pomeraniec I, Bryant JP, Chittiboina P, Heiss JD. Flexible thecoscopy for extensive spinal arachnoiditis. J Neurosurgery Spine 2022;36:325–35. doi: 10.3171/2021.4.SPINE21483. PMID: 34598155.

[3] Peng H, Conermann T. Arachnoiditis. StatPearls[Internet]. Treasure Island (FL): StatPearls Publishing; 2024.

[4] Long DM. Chronic adhesive spinal arachnoiditis: pathogenesis, prognosis, and treatment. Neurosurg Q 1992;2:296–320.

[5] Holmström U, Tsitsopoulos PP, Flygt H, Holtz A, Marklund N. Neurosurgical untethering with or without syrinx drainage results in high patient satisfaction and favorable clinical outcome in post-traumatic myelopathy patients. Spinal Cord 2018;56:873–882. doi: 10.1038/s41393-018-0094-y. PMID: 29588484.

[6] Inoue Y, Nemoto Y, Ohata K, Daikokuya H, Hakuba A, Tashiro T, et al. Syringomyelia associated with adhesive spinal arachnoiditis: MRI. Neuroradiology 2001;43:325–30. doi: 10.1007/pl00006049. PMID: 11338419.

[7] Zhang W, Liu Z, Wang K, Zhang L, Liu S, Zhang X, et al. Spinal adhesive arachnoidopathy, the disorder more than simply adhesive arachnoiditis: a comprehensive systematic review of 510 cases. CNS Neurosci Ther 2024;30:e70084. doi: 10.1111/CNS.70084. PMID: 39435986.

[8] Wang R, Zhou R, Chen Z, Gao S, Zhou F. The glial cells respond to spinal cord injury. Front Neurol 2022;13. doi: 10.3389/fneur.2022.844497. PMID: 35599739.

[9] Holmström U, Tsitsopoulos PP, Holtz A, Salci K, Shaw G, Mondello S, et al. Cerebrospinal fluid levels of GFAP and pNF-H are elevated in patients with chronic spinal cord injury and neurological deterioration. Acta Neurochir (Wien) 2020;162:2075–86. doi: 10.1007/S00701-020-04422-6. PMID: 32588294.

[10] Anderson TL, Morris JM, Wald JT, Kotsenas AL. Imaging appearance of advanced chronic adhesive arachnoiditis: a retrospective review. AJR Am J Roentgenol 2017;209:648–55. doi: 10.2214/AJR.16.16704. PMID: 28639826.

[11] Maillard J, Batista S, Medeiros F, Farid G, Santa Maria PE, Perret CM, et al. Spinal adhesive arachnoiditis: a literature review. Cureus 2023;15:e33697. doi: 10.7759/cureus.33697. PMID: 36788823.

[12] Aldrete J. Suspecting and diagnosing arachnoiditis. Pract Pain Manag 2006;6.

[13] Guyer DW, Wiltse LL, Eskay ML, Guyer BH. The long-range prognosis of arachnoiditis. Spine (Phila Pa 1976) 1989;14:1332–41. doi : 10.1097/00007632-198912000-00010. PMID: 2617363.

[14] Burton C V. Lumbosacral arachnoiditis. Spine (Phila Pa 1976) 1978;3:24–30. doi: 10.1097/00007632-197803000-00006. PMID: 148106.

[15] Orphanet. Arachnoiditis 2024. https://www.orpha.net/en/disease/detail/137817.

[16] Zhang W, Zhang X, Wang K, Liu Z, Zhang L, Liu S, et al. Single-nucleus transcriptome profiling provides insights into the pathophysiology of adhesive arachnoiditis. Biochim Biophys Acta Mol Basis Dis 2025;1871. doi: 10.1016/j.bbadis.2024.167655. PMID: 39755217.

[17] Brodbelt AR, Stoodley MA. Post-traumatic syringomyelia: A review. Journal of Clinical Neuroscience 2003;10:401–8. doi: 10.1016/S0967-5868(02)00326-0. PMID: 12852875.

[18] Jain N, Jaunozolina L, Putraima I, Auslands K, Millers A. Delayed spinal arachnoiditis with syringomyelia following aneurysmal subarachnoid haemorrhage: a case report with patient experience. Spinal Cord Ser Cases 2024;10. doi:/ 10.1038/S41394-024-00654-1. PMID: 38858362.

[19] Laitt R, Jackson A, Isherwood I. Patterns of chronic adhesive arachnoiditis following Myodil myelography: the significance of spinal canal stenosis and previous surgery. Br J Radiol 1996;69:693–8. doi:10.1259/0007-1285-69-824-693. PMID: 8949669.

[20] Nadeem SF, Baig AN, Tariq QUA, Shamim MS. Spinal arachnoiditis and syringomyelia: review of literature with emphasis on postinfectious inflammation and treatment. Surg Neurol Int 2022;13. doi: 10.25259/SNI_383_2022. PMID: 35928312.

[21] Nannini S, Koshenkova L, Baloglu S, Chaussemy D, Noël G, Schott R. Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review. J Neurooncol 2022;157:533–50. doi: 10.1007/s11060-022-03997-7. PMID: 35416575.

[22] Di Ieva A, Barolat G, Tschabitscher M, Rognone E, Aimar E, Gaetani P, et al. Lumbar arachnoiditis and thecaloscopy: brief review and proposed treatment algorithm. Cent Eur Neurosurg 2010;71:207–12. doi: 10.1055/s-0029-1243201. PMID: 20027540.

[23] Kainer MA, Reagan DR, Nguyen DB, Wiese AD, Wise ME, Ward J, et al. Fungal infections associated with contaminated methylprednisolone in Tennessee. New England Journal of Medicine 2012;367:2194–203. doi: 10.1056/nejmoa1212972. PMID: 23131029.

[24] Smith RM, Schaefer MK, Kainer MA, Wise M, Finks J, Duwve J, et al. Fungal infections associated with contaminated methylprednisolone injections. New England Journal of Medicine 2013;369:1598–609. doi: 10.1056/nejmoa1213978. PMID: 23252499.

[25] Centers for Disease Control and Prevention. Spinal and paraspinal infections associated with contaminated methylprednisolone acetate injections – Michigan, 2012-2013. MMWR Morb Mortal Wkly Rep. 2013 May 17;62(19):377-8.

[26] World Health Organization. WHO. 2023. Outbreak of suspected fungal meningitis associated with surgical procedures performed under spinal anaesthesia in US & Mexico 2023.

[27] Practice advisory for the prevention, diagnosis, and management of infectious complications associated with neuraxial techniques: an updated report by the American Society of Anesthesiologists Task Force on Infectious Complications Associated with Neuraxial Techniques and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology 2017;126:585–601. doi: 10.1097/ALN.0000000000001521. PMID: 28114178.

[28] El Homsi M, Gharzeddine K, Cuevas J, Arevalo-Perez J, Rebeiz K, Khoury NJ, et al. MRI findings of arachnoiditis, revisited. Is classification possible? Journal of Magnetic Resonance Imaging 2021;54:904–9. doi: 10.1002/jmri.27583. PMID: 33644967.

[29] Ottaiano AC, de Freddi TAL. “Sticky Spine”: A review of the imaging findings for spinal arachnoiditis. Neurographics 2022;12:169–75. doi: 10.3174/ng.2100062.

[30] Brenna CTA, Khan S, Poots C, Brull R. Association between perioperative neuraxial local anesthetic neurotoxicity and arachnoiditis: a narrative review of published reports. Reg Anesth Pain Med 2024;49:726–50. doi: 10.1136/RAPM-2023-104941. PMID: 38050164.

[31] De La Motte MB, Abbas R, Jouan F, Van Gysel D, Chauveheid MP, Papo T, et al. Systemic inflammatory disorders in patients admitted for aseptic meningitis. Clin Med 2018;18:132–137. doi: 10.7861/CLINMEDICINE.18-2-132. PMID: 29626017.

[32] Abhinav K, Bradley M, Aquilina K, Patel NK. Spinal arachnoiditis and cyst formation with subarachnoid haemorrhage. Br J Neurosurg 2012;26:574–5. doi: 10.3109/02688697.2011.651512. PMID: 22299598.

[33] Khan MU, Anthony J, Devlin J, Fraser A. Adhesive arachnoiditis in mixed connective tissue disease: a rare neurological manifestation. BMJ Case Rep 2016. doi: 10.1136/bcr-2016-217418. PMID: 27986694.

[34] Porcelli MJ, Tennant FS. Primer on Adhesive Arachnoiditis. JOFP-CA 2024;2. doi: 10.58858/010203.

[35] Tonk SS, Wilson GN. Similar Ehlers–Danlos Syndrome profiles produced by variants in multiple collagen genes. DNA 2025;5:11. doi: 10.3390/DNA5010011.

[36] Pasoglou V, Janin N, Tebache M, Tegos TJ, Born JD, Collignon L. Familial adhesive arachnoiditis associated with syringomyelia. American Journal of Neuroradiology 2014;35:1232–6. doi: 10.3174/ajnr.A3858. PMID: 24481329.

[37] Luchtmann M, Klammer A, Iova MA, Roth A, Mawrin C, Warnke JP. Combined endoscopic and microsurgical treatment of Tarlov cysts. Interdisciplinary Neurosurgery 2024;36:101925. doi: 10.1016/j.inat.2023.101925.

[38] Vaughan D, Bolger C, O'Brien DF. An interesting case of primary spinal arachnoiditis. Br J Neurosurg 2012;26:555–7. doi: 10.3109/02688697.2012.663516. PMID: 22369357.

[39] Arai A, Aihara H, Miyake S, Hanada Y, Kohmura E. Syringomyelia due to thoracic spinal stenosis with ossified ligamentum flavum. Neurol Med Chir 2011;51:157–9. doi: 10.2176/NMC.51.157. PMID: 21358164.

[40] Ross JS, Masaryk TJ, Modic MT, Delamater R, Bohlman H, Wilbur G, et al. MR imaging of lumbar arachnoiditis. AJR Am J Roentgenol 1987;149:1025–32. doi: 10.2214/AJR.149.5.1025. PMID: 3499773

[41] Hoffman G.S, Ellsworth C.A, Wells E.E, Franck W.A, Mackie R.W. Spinal arachnoiditis. what is the clinical spectrum? II. Arachnoiditis induced by Pantopaque/autologous blood in dogs, a possible model for human disease. Spine (Phila Pa 1976) 1983;8:541–51. PMID: 6648703

[42] Delamarter RB, Ross JS, Masaryk TJ, Modic MT, Bohlman HH. Diagnosis of lumbar arachnoiditis by magnetic resonance imaging. Spine (Phila Pa 1976) 1990;15:304–10. doi: 10.1097/00007632-199004000-00011. PMID: 2353276.

[43] Parenti V, Huda F, Richardson PK, Brown D, Aulakh M, Taheri MR. Lumbar arachnoiditis: does imaging associate with clinical features? Clin Neurol Neurosurg 2020;192. doi: 10.1016/j.clineuro.2020.105717. PMID: 32062307.

[44] Klekamp J. Treatment of syringomyelia related to nontraumatic arachnoid pathologies of the spinal canal. Neurosurgery 2013;72:376–89. doi: 10.1227/NEU.0b013e31827fcc8f. PMID: 23208064.

[45] Davidoff CL, Liu S, Wong JHY, Koustais S, Rogers JM, Stoodley MA. Treatment of syringomyelia in patients with arachnoiditis at the craniocervical junction. World Neurosurg 2017;107:565–73. doi: 10.1016/j.wneu.2017.08.064. PMID: 28842236.

[46] Moura da Silva LF, Buffon VA, Coelho Neto M, Ramina R. Non-schwannomatosis lesions of the internal acoustic meatus - a diagnostic challenge and management: a series report of nine cases. Neurosurg Rev 2015;38:641–8. doi : 10.1007/S10143-015-0638-Y. PMID: 25957055.

[47] Epstein NE, Agulnick MA. Perspective: Lumbar adhesive arachnoiditis (AA)/ chronic AA (CAA) are clinical diagnoses that do not require radiographic confirmation. Surg Neurol Int 2022;13. doi: 10.25259/SNI_943_2022. PMID: 36447842.

[48] Warnke JP, Köppert H, Bensch-Schreiter B, Dzelzitis J, Tschabitscher M. Thecaloscopy part III: First clinical application. Minimally Invasive Neurosurgery 2003;46:94–9. doi: 10.1055/S-2003-39341. PMID: 12761680.

[49] Tobita T, Okamoto M, Tomita M, Yamakura T, Fujihara H, Baba H, et al. Diagnosis of spinal disease with ultrafine flexible fiberscopes in patients with chronic pain. Spine (Phila Pa 1976) 2003;28:2006–12. doi: 10.1097/01.BRS.0000083595.10862.98. PMID: 12973149.

[50] Berthelot JM, Laredo JD, Darrieutort-Laffite C, Maugars Y. Stretching of roots contributes to the pathophysiology of radiculopathies. Joint Bone Spine 2018;85:41–5. doi: 10.1016/J.JBSPIN.2017.01.004. PMID: 28115269.

[51] Aldrete J A. Nerve root “irritation” or inflammation diagnosed by magnetic resonance imaging. Anesthesiology 2003;98:1294. doi: 10.1097/00000542-200305000-00040. PMID: 12717159.

[52] Villani LA, Digre KB, Cortez MM, Bokat C, Rassner UA, Ozudogru SN. Arachnoiditis, a complication of epidural blood patch for the treatment of low-pressure headache: a case report and systematic review. Headache 2021;61:244–52. doi: 10.1111/head.14076. PMID: 33583044.

[53] Her YF, McWilliams RT, Ovrom EA, Watson JC. Corticosteroid therapy in acute and subacute arachnoiditis – a case series. Int Med Case Rep J 2024;17:235–40. doi: 10.2147/IMCRJ.S445705. PMID: 38559495.

[54] Iqbal IM, Morris R, Hersch M. Adhesive arachnoiditis following inadvertent epidural injection of 2% chlorhexidine in 70% alcohol—partial recovery over the ensuing eight years. Anaesth Intensive Care 2018;46:572–4. doi: 10.1177/0310057X1804600606. PMID: 30447665.

[55] Tseng SH, Lin SM. Surgical treatment of thoracic arachnoiditis with multiple subarachnoid cysts caused by epidural anesthesia. Clin Neurol Neurosurg 1997;99:256–8. doi: 10.1016/S0303-8467(97)00086-3. PMID: 9491300.

[56] Gottschalk A, Schmitz B, Mauer UM, Bornstedt A, Steinhoff S, Danz B, et al. Dynamic visualization of arachnoid adhesions in a patient with idiopathic syringomyelia using high-resolution cine magnetic resonance imaging at 3T. J of Magn Reson Imaging 2010;32:218–22. doi: 10.1002/JMRI.22207. PMID: 20575079.

[57] Hatano K, Ohashi H, Kawamura D, Isoshima A, Nagashima H, Tochigi S, et al. MRI characteristics of syringomyelia associated with foramen magnum arachnoiditis: differentiation from Chiari malformation. Acta Neurochir (Wien) 2021;163:1593–601. doi: 10.1007/S00701-021-04845-9. PMID: 33881607.

[58] Ikushima I, Korogi Y, Hirai T, Yamashita Y. High-resolution constructive interference in a steady state imaging of cervicothoracic adhesive arachnoiditis. J Comput Assist Tomogr 2007;31:143–7. doi: 10.1097/01.RCT.0000230006.46145.16. PMID: 17259847.

[59] Tu YT, Chiang YH, Lin JH. Delta cord as a radiological localization sign of postoperative adhesive arachnoiditis: a case report and literature review. Diagnostics (Basel) 2023;13. doi: 10.3390/DIAGNOSTICS13182942. PMID: 37761311.

[60] Tsuchida R, Sumitani M, Azuma K, Abe H, Hozumi J, Inoue R, et al. A novel technique using magnetic resonance imaging in the supine and prone positions for diagnosing lumbar adhesive arachnoiditis: a preliminary study. Pain Practice 2020;20:34–43. doi : 10.1111/papr.12822. PMID: 31325409.

[61] Warnke JP, Mourgela S. Lumbale adhäsive arachnoiditis. Endoskopische subarachnoepidurostomie als neue behandlungsmöglichkeit [adhesive lumbar arachnoiditis. Endoscopic subarachnoepidurostomy as a new treatment]. Nervenarzt 2007;78:1182–7. doi: 10.1007/s00115-007-2289-x.

[62] Warnke JP, Mourgela S. Endoscopic treatment of lumbar arachnoiditis. Minimally Invasive Neurosurgery 2007;50:1–6. doi: 10.1055/s-2007-970056. PMID: 17546535.

[63] Petrasic JR, Chhabra A, Scott KM. Impact of MR neurography in patients with chronic cauda equina syndrome presenting as chronic pelvic pain and dysfunction. AJNR Am J Neuroradiol 2017;38:418–22. doi: 10.3174/AJNR.A4994. PMID: 28059708.

[64] Hackert J, Maßmann L, Sure U, Forsting M, Kleinschnitz C, Pul R, et al. Immunotherapies in chronic adhesive arachnoiditis - a case series and literature review. ENeurologicalSci 2021;24. doi: 10.1016/j.ensci.2021.100350. PMID: 34195394.

[65] Tennant F, Porcelli M, Guess S. Adhesive arachnoiditis: no longer a rare disease. MedCentral 2020;20.

[66] Gonzalez M. CE, Enriquez LE, Cruz A. C. Arachnoiditis following spinal anesthesia for Cesarean section. Colombian Journal of Anesthesiology 2012;40:150–2. doi: 10.1016/S2256-2087(12)70031-7.

[67] Assey E V., Sadiq AM, Swai MJ, Sadiq AM, Dekker MCJ. Idiopathic arachnoiditis of the cauda equina: a case report from Tanzania. Case Rep Neurol 2021;13:535–40. doi: 10.1159/000518379. PMID: 34720959.

[68] Iwatsuki K, Yoshimine T, Ohnishi YI, Ninomiya K, Moriwaki T, Ohkawa T. Syringomyelia associated with spinal arachnoiditis treated by partial arachnoid dissection and syrinx – far distal subarachnoid shunt. Clin Med Insights: Case Rep 2014;7:107–10. doi: 10.4137/CCRep.S14895. PMID: 25232285.

[69] Mauer UM, Gottschalk A, Kunz U, Schulz C. Arachnoscopy: A special application of spinal intradural endoscopy. Neurosurg Focus 2011;30. doi: 10.3171/2011.1.FOCUS10291. PMID: 21456934.

[70] Peek RD, Thomas JC, Wiltse LL. Diagnosis of lumbar arachnoiditis by myeloscopy. Spine (Phila Pa 1976) 1993;18:2286–9. doi: 10.1097/00007632-199311000-00025. PMID: 8278848.

[71] Kawauchi Y, Yone K, Sakou T. Myeloscopic observation of adhesive arachnoiditis in patients with lumbar spinal canal stenosis. Spinal Cord 1996;34:403–10. doi: 10.1038/SC.1996.72. PMID: 8963995.

[72] Manchikanti L, Abdi S, Atluri S, Benyamin RM, Boswell M V, Buenaventura RM, et al. An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: guidance and recommendations. Pain Physician 2013;16:S49–283. doi: 10.36076/ppj.2013/16/S49. PMID: 23615883.

[73] Shinu P, Morsy MA, Nair AB, Mouslem AKA, Venugopala KN, Goyal M, et al. Novel therapies for the treatment of neuropathic pain: potential and pitfalls. J Clin Med 2022;11. doi: 10.3390/jcm11113002. PMID: 35683390.

[74] Day P. Arachnoiditis: A brief summary of the literature. NZHTA Report 2001.

[75] Petty PG, Hudgson P, Hare WSC. Symptomatic lumbar spinal arachnoiditis: Fact or fallacy? Journal of Clinical Neuroscience 2000;7:395–9. doi: 10.1054/jocn.1999.0223. PMID: 10942659.

[76] Li T, Wang Y. A Global bibliometric study of spinal arachnoiditis: research trends and future directions. World Neurosurg 2025;194. doi: 10.1016/j.wneu.2024.123587. PMID: 39710197.

[77] Faigenbaum DC, Ruth JR, Kelleher D, Rubenstein AH. The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research. Lancet Haematol 2016; 3:e150-2. doi: 10.1016/S2352-3026(16)00007-7. PMID: 33523193

[78] Geraci J, Bhargava R, Qorri B, Leonchyk P, Cook D, Cook M, et al. Machine learning hypothesis-generation for patient stratification and target discovery in rare disease: our experience with Open Science in ALS. Front Comput Neurosci 2024;17. doi: 10.3389/fncom.2023.1199736. PMID: 38260713.

[79] Arachnoiditis and Chronic Meningitis Collaborative Research Network. ACMCRN | Empowering arachnoiditis patients through research, advocacy & support 2025. https://www.acmcrn.org/.

[80] StuffThatWorks. Introduction & overview | StuffThatWorks | crowdsourcing treatments that work 2024. https://www.stuffthatworks.health/introduction.

[81] Gagne JJ, Thompson L, O'Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: Methodological review. BMJ 2014;349. doi: 10.1136/bmj.g6802. PMID: 25422272.

[82] Barak-Levitt J, Held R, Synett Y, Kremer N, Hodak E, Sherman S. Hidradenitis suppurativa international online community: patient characteristics and a novel model of treatment effectiveness. Acta Derm Venereol 2022;102. doi: 10.2340/actadv.v102.1056. PMID: 35312027.

[83] Engel T, Dotan E, Synett Y, Held R, Soffer S, Ben-Horin S, et al. Self-reported treatment effectiveness for Crohn's disease using a novel crowdsourcing web-based platform. United European Gastroenterol J 2023;11:621–32. doi: 10.1002/ueg2.12424. PMID: 37370250.

[84] Held R, Blankstein A. Plantar fasciitis: a novel crowdsourcing approach to data collection and analysis. J Musculoskelet Res 2021;24. doi: 10.1142/S0218957721500238.

[85] Vears D, Gillam L. Inductive content analysis: A guide for beginning qualitative researchers 2022;23. doi: 10.11157/fohpe.v23i1.544.

[86] Innovation and Value Initiative, EveryLife Foundation for rare disease. Valuing rare disease treatments in healthcare: Real Experience, Real Impact. 2024.

[87] McQueen RB, Mendola ND, Jakab I, Bennett J, Nair K V., Németh B, et al. Framework for patient experience value elements in rare disease: a case study demonstrating the applicability of combined qualitative and quantitative methods. Pharmacoecon Open 2023;7:217–28. doi: 10.1007/s41669-022-00376-w. PMID: 36316575.

[88] Alifia RR, Sadeghi M, Eluru M, Jafari M, Grando MA. Bridging ethical gaps in digital health research: a framework for informed consent aligned with NIH guidance. BMC Medical Ethics 2025; 26:132. doi: 10.1186/s12910-025-01291-S. PMID: 41063017.

[89] Harris J, Germain J, McCoy E, Schofield R. Ethical guidance for conducting research with online communities: A scoping review of existing guidance. PLoS ONE 2024;19(5):e0302924. doi: 10.1371/journal.pone.0302924. PMID: 38758778.

[90] Fairweather D, Beetler DJ, McCabe EJ, Lieberman SM. Mechanisms underlying sex differences in autoimmunity. Journal of Clinical Investigation 2024;134:e180076. doi: 10.1172/JCI180076. PMID: 39286970.

[91] Coyle PK. What can we learn from sex differences in MS? J Pers Med 2021;11. doi: 10.3390/jpm11101006. PMID: 34683148.

[92] Aldrete JA. Chronic adhesive arachnoiditis. Br J Anaesth 2004;93:301–3. doi: 10.1093/bja/aeh591. PMID: 15251994.

[93] Fagundes W, Zottele MZ, Cavalcanti M, Silva YP. Neurosurgical challenges in recurrent adhesive arachnoiditis after spinal anesthesia for Cesarean delivery: case report and literature review. Cureus 2025;17:e86379. doi: 10.7759/CUREUS.86379. PMID: 40688970.

[94] Silva M, Halpern SH. Epidural analgesia for labor: current techniques. Local Reg Anesth 2010;3:143–53. doi: 10.2147/LRA.S10237. PMID: 23144567.

[95] Cesare N, Grant C, Nsoesie EO. Understanding demographic bias and representation in social media health data. WebSci 2019 - companion of the 11th ACM Conference on Web Science, Association for Computing Machinery; 2019, p. 7–9. doi: 10.1145/3328413.3328415.

[96] Whitaker C, Stevelink S, Fear N. The use of Facebook in recruiting participants for health research purposes: a systematic review. J Med Internet Res 2017;19:e290. doi: 10.2196/jmir.7071. PMID: 28851679.

[97] Shumway NK, Cole E, Fernandez KH. Neurocutaneous disease: Neurocutaneous dysesthesias. J Am Acad Dermatol 2016;74:215–28. doi: 10.1016/j.jaad.2015.04.059. PMID: 26775772.

[98] Yamada S, Lonser RR, Colohan AR, Yamada CT. Tethered cord syndrome in adult and late-teenage patients without neural spinal dysraphism. In: Yamada S, editor. Tethered cord syndrome in children and adults. 2nd ed, Stuttgart: Georg Thieme Verlag KG; 2010, p. 162–79. doi: 10.1055/b-002-80413.

[99] Phi JH, Lee DY, Jahng TA, Chung CK, Kim HJ. Tethered cord syndrome in adulthood: reconsidering the prognosis. J Korean Neurosurg Soc 2004;36:114–9.

[100] Oz O, Ulas U, Duz B, Yücel Mehmet, Odabasi Z. Electrophysiological findings in patients with adult tethered cord syndrome. Turk Neurosurg 2010;20:16–20.

[101] Nogués MA, Stålberg E. Electrodiagnostic findings in syringomyelia. Muscle Nerve 1999;22:1653–9.

[102] Hulens M, Bruyninckx F, Dankaerts W, Vansant G, De Mulder PA. Electromyographic abnormalities associated with symptomatic sacral Tarlov cysts. Pain Practice 2016;16:E81–8. doi: 10.1111/papr.12441. PMID: 26952047.

[103] Hulens M, Bruyninckx F, Somers A, Stalmans I, Peersman B, Greet V, et al. Electromyography and a review of the literature provide insights into the role of sacral perineural cysts in unexplained chronic pelvic, perineal and leg pain syndromes. Int J Phys Med Rehabil 2017;5. doi: 10.4172/2329-9096.1000407.

[104] Luthra K, Darwish Y, Ritter S, Gopal N, Benkovic S, Suri P, et al. Intercepting Intracept: A case report of idiopathic arachnoiditis. J Rehab and Pain Med 2023;1:168–75. doi: 10.37191/mapsci-jrpm-1(3)-018.

[105] Cornelson SM, Johnnie ED, Kettner NW. Neural mobilization in a 54-year-old woman with postoperative spinal adhesive arachnoiditis. J Chiropr Med 2018;17:283–8. doi: 10.1016/J.JCM.2018.07.004. PMID: 30846922.

[106] Ospelnikova TP, Shitova AD, Voskresenskaya ON, Ermilova E V. Neuroinflammation in the pathogenesis of neuropathic pain syndrome. Neurosci Behav Physiol 2023;53:27–33. doi: 10.1007/S11055-023-01387-8/METRICS.

[107] Yamada S, Won DJ, Pezeshkpour G, Yamada BS, Yamada SM, Siddiqi J, et al. Pathophysiology of tethered cord syndrome and similar complex disorders. Neurosurg Focus 2007;23:E6. doi: 10.3171/FOC-07/08/E6. PMID: 17961011.

[108] Shih P, Halpin RJ, Ganju A, Liu JC, Koski TR. Management of recurrent adult tethered cord syndrome. Neurosurg Focus 2010;29:1–5. doi: 10.3171/2010.3.FOCUS1073. PMID: 20594003.

[109] Hodges PW, Gandevia SC. Changes in intra-abdominal pressure during postural and respiratory activation of the human diaphragm. J Appl Physiol 2000;89:967–76. doi: 10.1152/JAPPL.2000.89.3.967. PMID: 10956340.

[110] Aktas G, Kollmeier JM, Joseph AA, Merboldt KD, Ludwig HC, Gärtner J, et al. Spinal CSF flow in response to forced thoracic and abdominal respiration. Fluids Barriers CNS 2019;16. doi: 10.1186/S12987-019-0130-0. PMID: 30947716.

[111] Zhang Z, Wang X, Jonas JB, Wang H, Zhang X, Peng X, et al. Valsalva manoeuver, intra-ocular pressure, cerebrospinal fluid pressure, optic disc topography: Beijing intracranial and intra-ocular pressure study. Acta Ophthalmol 2014;92:e475-80. doi: 10.1111/AOS.12263. PMID: 24020862.

[112] Depauw PRAM, Groen RJM, Van Loon J, Peul WC, Malbrain MLNG, De Waele JJ. The significance of intra-abdominal pressure in neurosurgery and neurological diseases: A narrative review and a conceptual proposal. Acta Neurochir (Wien) 2019;161:855–64. doi : 10.1007/S00701-019-03868-7. PMID: 30911831.

[113] Lloyd RA, Butler JE, Gandevia SC, Ball IK, Toson B, Stoodley MA, et al. Respiratory cerebrospinal fluid flow is driven by the thoracic and lumbar spinal pressures. J Physiol 2020;598:5789–805. doi: 10.1113/JP279458. PMID: 32990956.

[114] Heiss JD, Snyder K, Peterson MM, Patronas NJ, Butman JA, Smith RK, et al. Pathophysiology of primary spinal syringomyelia. J Neurosurg Spine 2012;17:367–80. doi: 10.3171/2012.8.SPINE111059. PMID: 22958075.

[115] Geneen LJ, Moore RA, Clarke C, Martin D, Colvin LA, Smith BH. Physical activity and exercise for chronic pain in adults: An overview of Cochrane Reviews. Cochrane Database Syst Rev 2017;1. doi: 10.1002/14651858.CD011279.PUB2. PMID: 28087891.

[116] Grooten WJA, Boström C, Dedering Å, Halvorsen M, Kuster RP, Nilsson-Wikmar L, et al. Summarizing the effects of different exercise types in chronic low back pain – a systematic review of systematic reviews. BMC Musculoskelet Disord 2022;23:49. doi: 10.1186/S12891-022-05722-X/TABLES/21. PMID: 35996124.

[117] Lima L V., Abner TSS, Sluka KA. Does exercise increase or decrease pain? Central mechanisms underlying these two phenomena. J Physiol 2017;595:4141–50. doi: 10.1113/JP273355. PMID: 28369946.

[118] Leitzelar BN, Koltyn KF. Exercise and neuropathic pain: a general overview of preclinical and clinical research. Sports Med Open 2021;7. doi: 10.1186/S40798-021-00307-9. PMID: 33751253.

[119] Jackson A, Isherwood I. Does degenerative disease of the lumbar spine cause arachnoiditis? A magnetic resonance study and review of the literature. British Journal of Radiology 1994;67:840–7. doi: 10.1259/0007-1285-67-801-840. PMID: 7953223.

[120] Epstein JA, Epstein BS, Lavine LS, Rosenthal AD, Decker RE, Carras R. Obliterative arachnoiditis complicating lumbar spinal stenosis. J Neurosurg 1978;48:252–8. doi: 10.3171/JNS.1978.48.2.0252. PMID: 624974.

[121] Cancino GG, López-Valdés JC, Valdez-Rodríguez A, Loreto-Lucas M, Vega-Moreno DA, Betancourt-Quiroz C, et al. Predisposing factors for failed back surgery syndrome following lumbar instrumentation: retrospective study. Cirugía de Columna 2025;3:253–9. doi: 10.35366/120969.

[122] Ahn M-W, Kim Y-Y, Byun W-M. The arachnoiditis-like nerve root distribution in the thecal sac of the degenerative disc diseases. J Korean Soc Spine Surg 1997;4:300–8. doi: 10.4184/jkss.1997.4.2.300.

[123] Klepinowski T, Orbik W, Sagan L. Global incidence of spinal perineural Tarlov's cysts and their morphological characteristics: a meta-analysis of 13,266 subjects. Surgical and Radiologic Anatomy 2021;43:855–63. doi: 10.1007/s00276-020-02644-y. PMID: 33452905.

[124] Carroll MB. Hypermobility spectrum disorders: A review. Rheumatol Immunol Res 2023;4:60–8. doi : 10.2478/rir-2023-0010. PMID: 37637226.

[125] Henderson FC, Austin C, Benzel E, Bolognese P, Ellenbogen R, Francomano CA, et al. Neurological and spinal manifestations of the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet 2017;175:195–211. doi: 10.1002/AJMG.C.31549. PMID: 28220607.

[126] Fitzcharles MA, Perrot S, Häuser W. Comorbid fibromyalgia: A qualitative review of prevalence and importance. Eur J Pain 2018;22:1565–76. doi: 10.1002/EJP.1252. PMID: 29802812.

[127] Wawrzyniak A, Lubiatowski P. Shoulder arthropathy secondary to syringomyelia: systematic review. EFORT Open Rev 2023;8:26–34. doi: 10.1530/EOR-22-0008. PMID: 36705617.

[128] Henke AM, Billington ZJ, Gater DR. Autonomic dysfunction and management after spinal cord injury: a narrative review. J Pers Med 2022;12. doi: 10.3390/JPM12071110. PMID: 35887607.

[129] Muro K, DiPatri Jr. AJ, McLone DG. The Cervical Tethered Spinal Cord. In: Yamada S, editor. Tethered Cord Syndrome in Children and Adults. Second, Stuttgart: Georg Thieme Verlag KG; 2010, p. 102–9. doi: 10.1055/b-002-80413.

[130] Her YF. A proposed multimodal therapy approach for the treatment of arachnoiditis. J Clin Med Case Stud 2024;9. doi: 10.4172/JClinMedCaseStud.9.2.001.

[131] Jha S. Algorithms at the gate - radiology's AI adoption dilemma. JAMA 2023;330:1615–6. doi: 10.1001/jama.2023.16049. PMID: 37801311.

[132] Bock A, Hswen Y. How artificial intelligence will enhance imaging access and analysis. JAMA 2024;331:1979–81. doi 10.1001/jama.2024.7251. PMID: 38787567.

[133] Wangberg SC, Andreassen HK, Prokosch HU, Santana SMV, Sørensen T, Chronaki CE. Relations between internet use, socio-economic status (SES), social support and subjective health. Health Promot Int 2008;23:70–7. doi: 10.1093/HEAPRO/DAM039. PMID: 18083686.

[134] Hasebrink U, Jensen KB, Bulck H Van Den, Hölig S, Maeseele P. Media audiences |changing patterns of media use across cultures: a challenge for longitudinal research. Int J Commun 2015;9:435–57.

[135] Faye F, Crocione C, Anido de Peña R, Bellagambi S, Escati Peñaloza L, Hunter A, et al. Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a Rare Barometer retrospective patient survey. European Journal of Human Genetics 2024;32:1116–26. doi: 10.1038/s41431-024-01604-z. PMID: 38755315.

[136] Baxter MF, Hansen M, Gration D, Groza T, Baynam G. Surfacing undiagnosed disease: consideration, counting and coding. Front Pediatr 2023;11. doi: 10.3389/fped.2023.1283880. PMID: 38027298.

[137] Ng IK, Tham SZ, Singh GD, Thong C, Teo DB. Medical gaslighting: a new colloquialism. American Journal of Medicine 2024;137:920–2. doi: 10.1016/j.amjmed.2024.06.022. PMID: 38936758.

[138] Shapiro D, Hayburn A. Medical gaslighting as a mechanism for medical trauma: case studies and analysis. Curr Psychol 2024;43:34747–60. doi: 10.1007/S12144-024-06935-0/TABLES/1.

[139] Halverson CME, Penwell HL, Francomano CA. Clinician-associated traumatization from difficult medical encounters: Results from a qualitative interview study on the Ehlers-Danlos Syndromes. SSM - Qualitative Research in Health 2023;3:100237. doi: 10.1016/J.SSMQR.2023.100237. PMID: 37426705.

[140] Rust R, Yin H, Buil BA, Sagare AP, Kisler K. The blood-brain barrier: a help and a hindrance. Brain 2025. doi: 10.1093/BRAIN/AWAF068. PMID: 39969549.

[141] Feigenbaum F, Parks SE, Chapple KM. Prospective validation of a quality-of-life measure for women undergoing surgical intervention for symptomatic sacral Tarlov cysts: the Tarlov cyst quality of life scale. World Neurosurg 2022;165:e276–81. doi: 10.1016/J.WNEU.2022.06.033. PMID: 35700862.